













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 









The role of PDGF-B/PDGFRβ signalling in 
definitive haematopoiesis 
 






PhD in Regenerative Medicine 







I, Diana Sá da Bandeira, declare that this dissertation is the result of my own 
work, except where explicitly indicated in the text.  
The data presented in this thesis has not been submitted for any other degree 
or professional qualification.   
 iv 
Abstract 
The first haematopoietic stem cells (HSCs) are generated in the dorsal aorta 
(DA) of the midgestation mouse embryo. Signals from the microenvironment 
are required for HSC generation. However, the signals and identity of cells 
releasing them in vivo remain unknown. In the present work, we identified at 
least three populations of perivascular cells surrounding the DA based on the 
expression of the perivascular cell markers NG2, PDGFRβ and αSMA. NG2+ 
PDGFRβ+ αSMA+ pericytes/vascular smooth muscle cells (PCs/vSMCs) and 
NG2- PDGFRβ+ αSMA- sub-pericytes (Sub-PCs) were found to be enriched 
in HSC-supportive genes described in the adult bone marrow (BM). As both 
populations express PDGFRβ, which has recently been shown to mediate 
HSC specification in zebrafish, and PDGF-B/PDGFRβ signalling is also 
required for the recruitment of pericytes to the developing blood vessel wall, 
we hypothesised that PDGF-B/PDGFRβ signalling is required to generate the 
first HSCs in vivo. To answer this question, we used PDGFRβ knock-out (KO) 
and PDGF-Bret KO mice, both of which have a defective pericyte recruitment 
to blood vessels and defective or absent PDGF-B/PDGFRβ signalling. Results 
from our haematopoietic progenitor assays (CFU-Cs) and transplantations 
show that the germline deletion of PDGFRβ affects both haematopoietic 
progenitor numbers and HSC activity in the E11 AGM. HSPCs in other 
haematopoietic organs are not affected at this stage. PDGF-Bret KO mice 
showed no defects in midgestation HSPCs, but AGM HSCs failed to 
reconstitute secondary recipients. Together, these data suggest that PDGF-
B/PDGFRβ signalling is required for AGM haematopoiesis. We found that 
perivascular stromal cells surrounding the DA are not affected by these 
mutations, nor the integrity of the blood vessel, suggesting that PDGF-
B/PDGFRβ signalling is not required for PC/vSMCs recruitment to the DA. We 
therefore hypothesised that PDGF-B/PDGFRβ signalling is either required in 
the niche for HSC specification and/or generation, and/or that PDGFRβ+ cells 
are precursors of HSCs. Tracing experiments using PDGFRβ-Cre;TdTomato 
mice found that a subset of AGM HSPCs derive from PDGFRβ-Cre precursors 
and that both Tomato- and Tomato+ E14 foetal liver (FL) and BM cells 
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reconstitute irradiated recipients. Together these data suggest that adult HSCs 
have distinct developmental origins, one of them deriving from PDGFRβ+ 
cells. In conclusion, our results define PDGFRβ signalling as a key component 
of the HSC generating niche in the mouse embryo, and that a subset of HSCs 





Blood stem cells (HSCs) have a high therapeutic value as they give rise to all 
the blood cells in the body. They are used to treat leukaemias and other 
diseases, but their use is limited to the availability of compatible donors. 
Understanding the mechanisms by which blood stem cells are generated 
during embryonic development will enable scientists to grow and expand them 
in a dish, decreasing the need for donors, and making blood stem cell-based 
therapies available to more patients. In the present work, we looked at the 
environment in which blood cells are first made in the mouse embryo and found 
that there are different populations of cells surrounding the dorsal aorta (DA) 
where HSCs are made, that express genes that were shown to support HSCs 
in the adult bone marrow. Two of these populations were shown to express a 
receptor called PDGFRβ. We found that the deletion of this receptor impairs 
the generation of HSCs in the DA. We also found that HSCs generated in the 
DA derive from PDGFRβ-expressing precursors and persist into adulthood, 
but not all HSCs derive from these precursors. In summary, we better 
characterised the HSC-generating “niche”, which can provide additional 
information on factors that are required to make HSCs in a dish, and found that 
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Chapter 1 General Introduction 
1.1 Haematopoietic stem cells 
1.1.1 Discovery and definition 
In the early 60’s, while James Till and Ernst McCulloch were conducting 
experiments on bone marrow (BM) sensitivity to radiation, they discovered that 
the transplantation of healthy murine BM cells into lethally irradiated recipients 
could regenerate the entire haematopoietic system (erythroid, myeloid and 
lymphoid lineages) [1,2], and rescue the mice from certain death. They found 
that the BM contained haematopoietic stem cells (HSCs), that were defined by 
their ability to repopulate all blood lineages upon transplantation into irradiated 
recipients and self-renew [2]. In more recent years, several studies suggest 
that HSCs are a more heterogeneous population of cells than initially thought 
[3–5]. Different subtypes of HSCs have been described with different 
properties such as lineage differentiation output (myeloid biased or lymphoid 
biased) [4,6,7], cell cycle status (cycling or quiescent) [8], repopulation kinetics 
and self-renewal (short-, intermediate- and long-term reconstituting HSCs) [5–
7,9]. HSCs can be enriched from a heterogeneous population of 
haematopoietic cells using different combinations of cell surface markers. 
However, this is not sufficient to identify functional HSCs. For this reason, 
transplantations are necessary to prove their presence.   
1.1.2 Clinical applications 
Because HSCs have the ability to give rise to the entire haematopoietic system 
upon transplantation and self-renew, they have a high therapeutic value. 
Haematopoietic stem cell transplantation (HSCT) of either autologous or 
allogeneic HSCs has been widely used to treat haematological malignancies, 
such as leukaemia, haemoglobinopathies and congenital blood disorders over 
the past 60 years [10]. It has so far been the only successful cellular therapy 
used on a large scale worldwide [11,12]. Transplantable HSCs are either 
derived from the BM, peripheral blood (PB) or umbilical cord blood of patients 
or donors. There are, however, issues associated with HSCT, such as 
infections and graft-versus-host disease that cause high mortality and 
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morbidity among patients [13]. Another limitation of HSCT is the lack of 
compatible donor cells.  
Generating functional haematopoietic stem and progenitor cells in vitro, either 
from induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs), 
has therefore been a long-term goal of haematologists for the past decades, 
as it would provide an unlimited source of blood cells for different therapies, 
drug studies, etc. For instance, HSCs could be used as vectors for gene 
therapy, as they could be genetically modified and transplanted back into 
patients. This would allow to not only treat haematological and autoimmune 
disorders such as sickle cell anaemia or SCID-X1 [14], but also to treat other 
genetic disorders, such as lysosomal storage disorders [15], providing an 
inexhaustible source of enzymes throughout the body. Although considerable 
progress has been made in recent years [16,17], the production of fully 
functional HSCs in vitro has not yet been achieved.  
Understanding the mechanisms underlying HSC specification, generation and 
maintenance in vivo can provide additional information required to replicate 
this process in vitro. One way to study these mechanisms is to look at the 
generation of the first adult-type HSCs during embryonic development in mice, 
as most of the processes are highly conserved between mouse and human 
[18].  
1.2 Murine haematopoiesis 
Although HSCs were first discovered in the adult BM, they are first generated 
during embryonic development, in the aorta-gonad-mesonephros region 
(AGM) of mammals that comprises the dorsal aorta, genital ridges and 
mesonephros.  
Murine embryonic haematopoiesis is a complex process that gives rise to 
different types of blood stem and progenitor cells at different stages and 
involves several organs, including the yolk sac (YS), placenta (PL), foetal liver 
(FL), AGM region and head. Haematopoietic cells are generated in three 
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different waves. The first two waves occur in the YS, while the third, where 
definitive HSCs are born, first occurs in the AGM region. 
1.2.1 Primitive haematopoiesis 
It is believed that the first haematopoietic cells derive from a mesodermal 
precursor called the haemangioblast, that can give rise to both endothelial and 
haematopoietic lineages [19,20]. Haemangioblasts are thought to emigrate 
from the primitive streak [21] into the YS, where they become committed to 
endothelial and haematopoietic fates and contribute to blood island formation 
[22,23]. Endothelial cells (ECs) within these blood islands give rise to primitive 
erythrocytes, macrophages and megakaryocyte progenitors from embryonic 
day 7 (E7) [24–27]. Primitive erythrocytes are nucleated, express embryonic 
haemoglobins (ε and βH1), and disappear by E9 [24,26]. These primitive 
erythrocytes are most likely required to provide the growing embryo with 
oxygen, and the macrophages for phagocytosis during tissue remodelling [28]. 
1.2.2 Definitive haematopoiesis 
1.2.2.1 Second wave of haematopoiesis 
Partially overlapping with the first wave of haematopoiesis, a second wave 
occurs in the YS, giving rise to erythroid-myeloid progenitors (EMPs) at E8.25, 
right before the onset of circulation [29,30]. This second wave marks the 
beginning of definitive haematopoiesis, as EMP-derived erythrocytes undergo 
enucleation and express the adult β-major globin, unlike their primitive 
counterpart that express embryonic βH1 globin and are nucleated [24].  Once 
circulation is established, EMPs quickly migrate to other organs. They can be 
detected in the placenta at E9 [31] and colonise the embryonic liver from E9.5 
[24] that becomes a major site for haematopoiesis at E11-E12 [32]. When 
circulation starts at E8.25, EMP-derived macrophages migrate to other tissues, 
where they become tissue resident macrophages that persist into adulthood 
[33]. Some lymphoid progenitors, immune-restricted lympho-myeloid 
progenitors and mast cells are also generated during the second wave in the 
YS. These lymphoid progenitors can be detected in the YS and aorta at E8.5 
[34–36], while lympho-myeloid progenitors and mast cells are found in the YS 
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from E9.5 [37,38]. It was also demonstrated that both the E9 YS and the E8.5 
para-aortic splanchnopleura (P-Sp) which evolves into the AGM, contain HSCs 
capable of long-term multilineage reconstitution of newborn mice, but fail to 
reconstitute adult recipients [34,39]. Haematopoietic progenitors (HPs) 
generated in the first waves of haematopoiesis also play a role in HSC 
generation in the AGM through the release of pro-inflammatory signals [40–
43].  
1.2.2.2 HSC generation 
In the third wave of haematopoiesis, starting at E10.5, the first adult-type HSCs 
are generated in the AGM region of the embryo [44,45]. They are defined by 
their ability to repopulate the entire blood system of adult irradiated recipients 
and to self-renew. AGM explant cultures showed that HSCs are autonomously 
generated in the AGM region [44], more specifically, in the ventral aspect of 
the dorsal aorta (DA) [46–48] through a process called endothelial to 
haematopoietic transition (EHT). HPs are found in the whole DA, while HSCs 
are localised on the ventral aspect, in haematopoietic clusters in close contact 
with the endothelium [46–48]. HSCs in these clusters express CD34, CD45 
and cKit [47,49,50]. Such clusters have also been described in human, chick, 
zebrafish and amphibian embryos [49–52]. 
Up until recently, it was believed that the AGM region only produces 1-2 
functional HSCs [53,54]. Although this quantification was defined based on 
limiting dilution experiments, this conclusion relied on the disruption, 
dissociation and transplantation of AGM cells, which could lead to an 
underestimation of the real number of HSCs. Two recent studies conducted on 
the zebrafish zebrabow model [55] as well as in confetti mice [56] used live 
imaging and multicolour lineage tracing without disrupting the DA to better 
quantify HSCs generated in the DA. With these models, at least 30 HSC clones 
were found in zebrafish at the peak of aortic haematopoiesis [55], and between 
600 and 700 developmental precursors at E10.5-E11.5 contributed to adult 
haematopoiesis in the mouse [56]. AGM HSCs express CD45 [47], Ly6A 
(Sca1) [47,48], cKit, CD34 [32], SCL [57] and GATA2 [58,59], however, 
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expression of these markers is not exclusive to HSCs, making it impossible to 
isolate them and detect them without resorting to transplantations.  
Following HSC generation in the AGM, HSCs can also be found in the umbilical 
and vitelline arteries [60], head [61], placenta, YS and FL as well as in 
circulation [44,45,62,63]. The FL is colonised from late E9 by HPs made in 
other haematopoietic organs [64,65], and from E11, by HSCs. In the FL HSCs 
are believed to mature and expand [53,66], before definitively migrating into 
the foetal BM from E15.5 onwards, where they reside for the whole life-span 
of the mouse [67]. Several studies have proposed that the PL autonomously 
generates HSCs, [31,68]. The E8 YS and P-Sp have also been shown to 
harbour HSC precursors that can maturate into definitive HSCs when co-
cultured with AGM stromal cells [69]. As these studies have mainly relied on 
explant cultures or co-cultures with OP-9 cell lines, it remains unclear whether 
adult-type HSCs are normally produced by these organs during development 
in vivo. In addition, circulation is established around E8.25 [70], from which 
point, haematopoietic cells enter circulation, making it difficult to determine 
whether HSCs found in the YS and PL are generated in situ, as they are 
detected after the generation of HSCs by the AGM [71].  
1.2.2.3 Endothelial to haematopoietic transition  
The observations that haematopoietic clusters and the aortic endothelium are 
closely associated, and that HSCs share common markers with ECs such as 
CD31, CD34, VE-Cadherin, Tie-2 and Flk-1 and are morphologically similar 
[21,50,72–74], led to the hypothesis of an endothelial origin for HSCs.  
Endothelial to haematopoietic transition is the process where specialised ECs 
called haemogenic endothelial cells (HECs) [75] transdifferentiate into adult-
type HSCs [52,76–79]. This process has been well described in the dorsal 
aorta and is conserved across vertebrates [52,80,81]. More recently, EHT has 
also been described in the BM of chickens and mice [82], as well as in the 
midgestation mouse head [61,83]. It is unclear whether it occurs in other 
organs, although the presence of HECs and budding haematopoietic cells from 
HECs have also been described in the PL and YS [84].  
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During aortic EHT, HSCs become part of a cluster of haematopoietic cells, 
where they maturate through different stages (pro-HSC, pre-HSC type I and 
pre-HSC type II) [85–87]. Haematopoietic cells in these clusters are 
heterogeneous [88], and many are thought to come from other haematopoietic 
organs such as the YS and PL through circulation [40].  
Two main transcription factors are required for EHT: Gata2 [58,89–91] and 
Runx1 [76,79,92,93]. Mice deficient for Gata2 and Runx1 die at E10.5 and 
E12.5, respectively, with foetal liver anaemia, haemorrhages and the lack of 
definitive haematopoiesis [93]. Both are required for HSC generation from 
HECs, but Gata2 expression is also essential for HSC survival [91], while 
Runx1 appears to only be necessary for EHT [79]. Both factors are expressed 
in the YS at E8, and from E8.5 to E11.5 they are expressed by some ECs of 
the aorta, umbilical and vitelline arteries, placenta and head, as well as in 
HSPCs [47,50,61,68,94,95]. Runx1 expression is also found in some 
mesenchymal stromal cells in the murine DA [47], but is restricted to the 
endothelium and HSPCs in zebrafish [96] and chick embryos [97]. These 
transcription factors were shown to be regulated by signalling pathways such 
as Notch and Bmp4/TGFβ [97–100].  
1.2.2.4 Foetal liver and foetal BM haematopoiesis 
At around E9, the FL starts being colonised by circulating HPs (and by HSCs 
from E11 on) and becomes a major haematopoietic organ between E11-E12, 
but is not capable of de novo generation of HSCs [32]. Co-cultures of AGM-
derived HSCs with E14.5 FL non-haematopoietic cells, showed that the FL 
microenvironment supports HSC expansion and engraftment [66], suggesting 
that it promotes the maturation and expansion of HSPCs generated in other 
organs. In addition, there are more HSCs in the FL than the ones produced in 
the AGM alone [53], but it is likely that they come from the additive production 
by the AGM, placenta and YS [62] and subsequent expansion in the FL. 
However, ex-vivo experiments have provided evidence that a pre-HSCs 
population produced from E9.5 to E11.5 in the AGM (undetectable by 
transplantation assays) can explain the larger number of mature HSCs found 
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in the E12.5 FL through a quick maturation process [101]. This evidence was 
recently supported by lineage tracing data and clonogenic analyses using 
confetti mice that suggest that the FL is more likely a place for HSC maturation 
rather than expansion [102]. Only a three-fold expansion in HSPCs that 
contribute to adult peripheral blood was observed in the FL between E11.5 and 
E15.5 [102]. The foetal thymus and spleen also become colonised by HSCs 
from E12 onwards, to differentiate into T and B cells, respectively [103]. From 
E15.5 onward, HSPC numbers sharply decrease in the FL and start migrating 
to the foetal BM [104,105]. 
1.2.3 Adult bone marrow haematopoiesis 
Following FL haematopoiesis, HSCs migrate to the BM, where they reside and 
provide a constant pool of blood cells and progenitors throughout adulthood. 
The main difference between HSCs found in the adult BM and their foetal 
counterpart is that foetal HSCs are highly proliferative while BM HSCs are 
mostly quiescent. The BM functions as a “niche” that regulates HSC 
maintenance, self-renewal and differentiation. The concept of niche was first 
defined in 1978 by Raymond Schofield, as a specialised microenvironment in 
a specific anatomical location that regulates stem cell proliferation, 
quiescence, self-renewal and differentiation [106]. In the BM, HSCs are found 
in the endosteal surface of trabecular bone, as well as in vascular sinusoids 
[107]. Both locations act as distinct niches for HSCs within the same organ, 
and contain distinct cell populations that have been shown or suggested to 
have a role in HSC homeostasis. Osteoblasts for example, have been 
implicated in HSC support in the BM [108]. LTR-HSCs have been reported to 
localise in close proximity to osteoblasts that respond to BMPR1A. An increase 
in the number of these osteoblasts was shown to correlate with an increase in 
HSC numbers in the murine BM [108]. Another study found that mouse BM 
osteoblasts are activated by the parathyroid hormone upregulate Jagged-1 
(Notch signalling), which consequently leads to an increase in the number of 
HSCs in the BM [109]. BM mesenchymal stem/stromal cell (MSC) lines were 
also shown to support BM HSPCs in culture [110,111], and HSC engraftment 
potential was increased after co-culture with BM MSCs [112] or when co-
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transplanted with BM-derived MSCs [113]. Other types of MSC-like cells are 
located in perivascular locations in the BM, namely pericytes (PCs), that were 
shown to support BM haematopoiesis [114–118]. In the human BM sinusoids 
for example, a population of perivascular cells expressing CD146, when 
transplanted into immunodeficient mice, was shown to form ossicles 
containing donor-derived bone and sinusoids, and host-derived ECs and HCs 
[118]. These data suggest that CD146+ BM cells have the ability to create a 
haematopoietic cell supportive microenvironment. These cells were also 
shown to express other pericyte/vascular smooth muscle cell (vSMC) markers 
such as αSMA, NG2 and PDGFRβ, as well as HSC niche related transcripts, 
such as JAG1 (Jagged-1), CDH2 (N-Cadherin), CXCL12 (C-X-C motif 
chemokine 12) and SCF (Stem cell factor or Kit ligand) [118] that have been 
implicated in HSC maintenance in the adult BM [119–121]. CD146+ 
perivascular cells were also described in the human foetal BM and white 
adipose tissue, and have the ability to support human cord blood HSCs in co-
culture experiments [117]. These cells were shown to have the capacity to 
engraft primary and secondary recipients, suggesting that they support HSC 
maintenance and self-renewal [117]. These CD146+ foetal BM and white 
adipose tissue perivascular cells were also shown to express NES (Nestin), 
CXCL12 and LEPR (Leptin receptor) [117], also described in BM perivascular 
cells with HSC-niche activity [115,120,122].  
Nestin+ perivascular cells with MSC potential and closely associated with 
adrenergic nerve fibres and HSCs were identified within the murine BM 
parenchyma [122]. They were shown to highly express HSC maintenance 
genes such as Cxcl12, Adrb3 (beta-3 adrenergic receptor) and Angpt1 
(Angiopoietin-1). Depletion of Nestin+ cells with diphtheria toxin using Nes-
CreERT2 mice led to a decrease of BM HSC numbers, due to a reduction in 
HSC homing ability, suggesting a putative role for Nestin+ perivascular cells in 
HSC trafficking [122]. These Nestin+ cells were further purified into a 
Nes+CD51+PDGFRα+ subset, that express higher levels of HSC regulatory 
genes such as Cxcl12, Angpt1 and Scf [123]. They also found that PDGFRα+ 
CD51+ cells in the human foetal BM correspond to a subset of CD146+ cells 
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that also express Nestin, and are enriched in HSC niche activity. When 
cultured as mesenspheres (MSC spheroid cultures), these cells were shown 
to have the potential to self-renew and transfer the hematopoietic 
microenvironment in ectopic grafts [123], similar to CD146+ perivascular cells 
[118]. Nestin-expressing cells that also express CD105 were also described in 
the human foetal and adult BM  and were shown to support HSC maintenance 
and self-renewal upon transplantation after co-culture with CD34+ human cord 
blood cells [124]. Additional heterogeneity among Nestin-expressing cells was 
found in the murine BM. A subset of Nes-GFP+ cells surrounding arterioles 
was also shown to express NG2, and HSCs located in these vessels were 
shown to be quiescent [114]. Conditional depletion of NG2+ cells using NG2-
creERTM/iDTR mice led to a change in location of HSCs further from the 
arterioles and a switch to a non-quiescent state [114]. These data suggest that 
NG2+ Nes-GFP+ cells surrounding arterioles are important for HSC 
quiescence. This study also showed that there are Nes-GFP+ cells 
surrounding the sinusoids, but unlike arteriolar Nes-GFP+ cells, GFP 
expression is much dimmer, and they do not express NG2 [114]. These 
sinusoidal cells mostly overlap with SCF-expressing LepR+ cells identified by 
Ding et al. in 2012 [115]. Deletion of Scf in LepR+ cells led to a reduction in 
the number of BM HSCs [115]. In addition, conditional deletion of Cxcl12 from 
LepR+ cells also led to a reduction of HSPCs in the BM, in parallel to an 
increase in their frequency in circulation [116], suggesting that LepR+ cells 
might also be part of an HSC-maintenance niche in the BM.  
Overall, different perivascular cell populations, some of which partially overlap, 
were shown to differentially regulate HSCs in the BM of both mice and humans. 
In addition, the BM was recently shown to generate HSCs de novo from HECs 
[82]. 
1.3 The HSC-generating microenvironment 
1.3.1 The AGM 
In the mouse embryo, the P-Sp mesoderm develops at the beginning of E9 
into the AGM region, which is composed of the dorsal aorta, genital ridges and 
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mesonephros. The AGM was shown to have the potential to expand HSCs in 
explant cultures [44]. In addition, AGM-derived mesenchymal stromal cell lines 
were established from midgestation embryos, and several of these lines were 
shown to support haematopoiesis [125], suggesting that AGM stromal cells are 
heterogeneous. These data led to the hypothesis that the AGM contains some 
stromal cells that function as a niche and/or are necessary for proper HSC 
specification. In addition, like many cell populations in the BM that support 
haematopoiesis, several AGM stromal clones and cell lines have the ability to 
differentiate into several mesenchymal lineages, while other haematopoietic 
tissues cannot [126,127]. The differentiation potential of some of the 
supportive cell lines was shown, however, to not be correlated with their ability 
to support HSCs, but rather to their site of origin [126]. Further analyses of the 
HSC-supportive stromal clones revealed that BMP4 is a regulator of AGM 
HSCs, which express BMP receptors [128]. BMP4 expression is mainly 
detected in mesenchymal cells located on the ventral aspect of the DA, many 
of which are in close proximity to nascent Ly6A-GFP+ cells in E11 intra-aortic 
haematopoietic clusters (IAHCs) [128]. A similar pattern of BMP4 expression 
was also observed in humans [129]. Inhibition of the Bmp4 pathway in E11 
murine explant cultures was found to impair HSC activity [128]. However, BMP 
activation might only be required for HSC maintenance after E11. BMP 
inhibition with Noggin, which is expressed by the ventral mesenchyme and 
IAHCs at E10.5 was shown to be crucial for HSC maturation in the E10.5 AGM 
[130]. Another player in the Bmp4 pathway is BMPER, which is expressed on 
the ventral side of the AGM [131]. It was shown to have agonistic effects on 
BMP4 at low concentrations and antagonistic effects at high concentrations. 
BMPER was shown to increase between E9.5 and E10.5 and to be required 
from E9.5 in the maturation of pro-HSCs [131].  
The polarisation of HSC emergence to the ventral aspect of the DA was shown 
to be due to inhibitory signals from the dorsal aspect of the DA and dorsal 
tissues, and activating signals from the ventral aspect of the DA and ventral 
tissues. The gut, located ventrally from the DA was proposed to be a source 
of Hedgehog proteins that lead to early HSC induction in AGM explant cultures 
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with surrounding tissues [132]. More recently, a more complex interplay of 
signalling pathways from three different compartments of the AGM (ventral 
aspect, dorsal aspect and urogenital ridges) was proposed to be required for 
HSC generation [130]. Explant cultures of only the ventral part of the aorta at 
E10.5 produce less HSCs than explants containing both the ventral and dorsal 
parts. This increase in definitive HSCs was shown to be mediated by Sonic 
Hedgehog (Shh) which is secreted dorsally [130]. SCF was also shown to be 
a positive regulator for HSCs, and is produced by the ventral mesenchyme as 
well as the urogenital ridges, lateral to the DA [130]. Notch expression was 
also found in ECs and HCs of the chick and mouse aortas, and the 
downregulation of Notch ligands was shown to be required for the onset of 
Runx1 expression and initiation of aortic haematopoiesis [97]. Like in the adult 
BM [133], the sympathetic nervous system (SNS) was found to play a role in 
AGM haematopoiesis. Gata3, a transcription factor highly expressed in the 
AGM at the time of HSC generation, was shown to be crucial for the production 
of catecholamines by the SNS which in turn are required for HSC generation 
[134].  
In conclusion, a complex spatiotemporal interplay between different embryonic 
regions, cell types and signalling pathways is required for HSC generation in 
the AGM. 
1.3.2 Dorsal aorta formation 
At E8, a pair of dorsal aortae starts developing. They fuse together from E9.5 
onwards from the anterior to the posterior part of the embryo [135]. Aortic 
endothelial cells have two separate origins. The roof and sides of the DA derive 
from the somites (paraxial mesoderm), while the aortic floor derives from the 
splanchnopleura (lateral plate mesoderm) [136]. In the chick embryo, 
endothelial cells in the aortic floor are replaced by paraxial mesoderm following 
HSC generation. This replacement has been proposed to explain the transient 
nature of HSC generation in the AGM [136–138]. However, lineage tracing 
data suggest that this replacement does not occur on ventral ECs in the murine 
DA, as they still express the lateral plate mesoderm reporter Hoxb6-cre [139].   
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As the DA develops, the aortic endothelium is surrounded by several layers of 
mesenchymal stem/stromal cells. At E10.5, a layer of PCs or vSMCs 
expressing αSMA and NG2 is found in close contact to the endothelium 
[140,141]. Similar to DA endothelial cells, stromal cells and vSMCs on the 
lateral and dorsal aspects of the DA derive from the somites, while the ones 
on the aortic floor derive from the lateral plate mesoderm [139]. Interestingly, 
stromal cells of the aortic floor were shown to be replaced by paraxial 
mesoderm-derived cells at E11.5 [139]. Experiments impairing the migration 
of the splanchnopleual mesoderm to the ventral aspect of the DA in the chick 
embryo found that this tissue is required for the onset of Runx1 expression and 
subsequent formation of IAHCs [97]. These data support the idea that signals 
from the subaortic mesenchyme are required for HSC emergence. 
1.4 PDGF-B/PDGFRβ signalling 
Platelet-derived growth factors (PDGFs) are growth factors that control cell 
growth and proliferation through the binding to the tyrosine kinase receptors 
PDGFRα and PDGFRβ. Binding of PDGFs to these receptors leads to their 
dimerization and initiation of their downstream signalling cascades. PDGFs are 
secreted by platelets, ECs, monocytes/macrophages, SMCs, fibroblasts, 
placenta cytotrophoblasts, neurons, and some glial cells [142,143]. In addition, 
they have been shown to affect the in vitro growth, migration and function of 
MSCs. They modulate cell functions such as the production of extracellular 
matrix components [144,145], and contraction [146,147]. Not much is known 
about the role of PDGF-B/PDGFRβ signalling in haematopoiesis, but a few 
recent studies have shed some light on its role during haematopoietic 
development in different species.  
For instance, in zebrafish, it was shown that trunk neural crest cells need to 
associate with the DA in order to initiate aortic haematopoiesis [148]. 
Morpholino knock down of pdgfra and pdgfrb halted neural crest cell migration 
to the ventrolateral sides of the DA. Consequently, the haematopoietic 
programme failed to initiate in the DA of these morphants, seen by the absence 
of runx1 and cmyb expression [148]. Pdgfrb was also found to be a 
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downstream target of Hif1α [149], which was shown to be required for HSC 
development in zebrafish [150,151]. Lim et al., also found that morpholino 
knock down as well as dominant negative pdgfrb expression led to the 
reduction in HSPC formation in the DA, and pdgfb overexpression led to their 
increase [149].  
In Drosophila, a different role for PDGF/VEGF receptor (a homolog of 
vertebrate PDGFRs) was described. Deletion of PDGF/VEGF was found to 
lead to the apoptosis of haemocytes (cells of the immune system of 
invertebrates), followed by their phagocytosis by other blood cells [152].  
In the mouse, E9 YS and embryoid bodies were found to contain 
haemangioblasts expressing PDGFRβ, CD31, Flk1 and CD41 [153]. 
Constitutive activation of PDGFRβ or ubiquitous expression of PDGF-B in 
recombinant mouse models was shown to promote a decrease in CD41+ 
expressing cells in E9.5 YS, and an increase in vascular remodelling [153], 
suggesting that in the YS, PDGF-B/PDGFRβ signalling acts as an “on” switch 
for endothelial cell development, and an “off” switch for haematopoietic cell 
development. However, it remains unknown whether the deletion or 
downregulation of PDGF-B or PDGFRβ would lead to an increase in YS 
haematopoiesis. PDGFRβ expression was also observed in placenta 
trophoblasts, which communicate with placental ECs via PDGF-B/PDGFRβ 
signalling [154]. The deletion of PDGFRβ, or PDGF-B, was shown to lead to 
the premature differentiation of erythroblasts into mature erythroid cells [154], 
suggesting that PDGFRβ signalling plays a role in the maintenance of 
erythroblasts in a more undifferentiated state.  
In the AGM, PDGFRβ was recently found to be expressed in a few cell layers 
underneath the endothelium of the E10.5 DA [155], and is upregulated in some 
HSC-supportive embryonic stromal cell lines [156]. However, whether it plays 
a role in murine haematopoiesis is still unknown.  
To study murine PDGF-B/PDGFRβ signalling in vivo, several mouse models 
have been made, namely PDGFRβ KO mice and PDGF-Bret KO mice 
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[157,158], which were used in this study. PDGFRβ KO embryos have a normal 
development until around E16, after which they show severe defects in the 
kidney due to the absence of mesangial cells, they are thrombocytopenic and 
anaemic, and have severe haemorrhages. These embryos die around birth, 
possibly caused by oxygenation defects due to the haematological disorders 
and haemorrhaging [157]. PDGF-Bret KO mice have a mutation in the PDGF-
B retention motif, which is required for the binding of PDGF-B to the 
extracellular matrix surrounding ECs and forming a PDGF-B gradient 
necessary for pericyte and vSMC recruitment to the blood vessel wall. Deletion 
of this retention motif leads to a disruption of this gradient, and 
pericytes/vSMCs are defectively recruited to the endothelium [158,159]. Unlike 
PDGFRβ KO mice, PDGF-Bret mice mice survive into adulthood, but are 
slightly growth retarded, and have reduced female fertility. PDGF-Bret embryos 
also show defects in kidney glomeruli and proteinuria, but milder compared to 
PDGFRβ KO embryos [158]. In addition, they also have a progressive and 
severe deterioration of the retina during adulthood [158].  
1.5 Summary 
The first adult-type HSCs are generated in the dorsal aorta of the mid-gestation 
mouse embryo. Stromal cells surrounding the DA play a role in HSC 
specification and/or generation. However, the identity of these cells and the 
signals involved remain poorly understood. The present work aims to address 
this by better characterising the stromal cells surrounding the DA at the time 




Chapter 2 Materials and methods 
2.1 Mice 
Mice were bred and housed at the MRC Centre for Regenerative Medicine, 
Edinburgh, UK. PDGFRβ KO mice [157] were maintained heterozygous 
(PDGFRβ+/-) in a C57BL/6J background; PDGF-Bret mice [158] were 
maintained either as heterozygous (PDGF-Bret/+) or homozygous (PDGF-
Bret/ret) in a C57BL/6J background; PDGFRβ-Cre (Tg(Pdgfrb-cre)1Rha) [160], 
TdTomato mice (JAX stock #007914) [161], Runx1-IRES-GFP mice 
(Runx1tm4Dow) [162] and mTmG mice (JAX stock #007576) [163] were 
maintained homozygous in a C57BL/6J background. The day of vaginal plug 
detection is designated as E0.5. All experiments were performed under a 
Project Licence granted by the Home Office (UK), approved by the University 
of Edinburgh Ethical Review Committee, and conducted in accordance to local 
guidelines. 
PDGFRβ KO mice [157] were generated by electroporation of a targeting 
vector into mouse ES cells and subsequent injection of positively selected ES 
cells into blastocysts. The targeting vector contained a neomycin 
phosphotransferase expression cassette (striped box, Figure 1A) inserted 
between the SmaI and EcoRV restriction sites, replacing a 1.8kb sequence of 
the pdgfrb locus by homologous recombination (Figure 1A). PDGFRβ KO mice 
die at birth or slightly before, and embryos are haemorrhagic, 
thrombocytopenic, anaemic and lack mesangial cells in the kidneys leading to 
defective kidney glomeruli (glomerulosclerosis) [157].  
PDGF-Bret KO mice [158] were generated by targeting a loxP-flanked PGK-
neomycin cassette into intron 5, and a premature translation stop codon with 
a HindIII restriction site into exon 6 of the pdgfb gene in mouse ES cells (Figure 
1B). Heterozygous mice were produced and crossed with protamine-Cre mice 
in order to delete the PGK-neomycin cassette and generate the pdgf-bret allele. 
In PDGF-Bret KO mice, PDGF-B lacks the C-terminal retention motif that allows 
its binding to heparan sulphate proteoglycans located in the extracellular 
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matrix surrounding ECs. Recombinant PDGF-B lacking the C-terminal 
retention motif is still functional [164]. KO mice survive into adulthood, but 
exhibit a severe deterioration of the retina, glomerulosclerosis, and proteinuria. 
vSMCs and pericytes have an abnormal organisation, where they partially 
detach from the endothelium due to the lack of a PDGF-B gradient around the 
endothelium required for their normal recruitment [158].  
Runx1-IRES-GFP mice [162] were generated by knocking in Runx1 cDNA in 
frame into exon 4 of the endogenous Runx1 allele (from exon 4), followed by 
an IRES-GFP sequence and polyadenylation cassette into E14 mouse ES 
cells. This led to the creation of an artificial exon 4 containing the full 3’ coding 
region of the gene (Figure 1C). Successfully targeted ES cell clones were 
injected into C57BL6 blastocysts. As the new allele is under the endogenous 
Runx1 promoter, Runx1 expression level remains physiological, overcoming 
any potential issues in haematopoietic cells, which are sensitive to Runx1 
dosage [165,166]. In addition, the IRES-GFP sequence allows for normal 
biological activity of RUNX1. Unfortunately, GFP expression was only 
detectable by flow cytometry, but not by eye under a fluorescence microscope, 
nor by immunohistochemistry. Several immunostaining protocols with and 
without anti-GFP staining were tested, but no GFP was ever detected (not 
shown).  
PDGFRβ-Cre mice were generated by pronuclear injection of fertilised 
129/C57BL6 oocytes with a vector containing a fragment of the Pdgfrb 
promoter fused to a Cre recombinase followed by an SV40 polyadenylation 
signal. No additional information regarding the construct was reported on this 
mouse model. This mouse has been used in the study of pericytes and vSMCs, 





Figure 1. Generation of PDGFRβ KO, PDGF-Bret KO and Runx1-IRES-GFP mice  
Representative scheme of the restriction maps of the loci (original and targeted) of the 
PDGFRβ KO, PDGF-Bret KO and Runx1-IRES-GFP transgenic mouse strains used in this 
study, and their respective targeting vectors. This figure was based on maps provided in the 
original publications. Some exons are represented as white solid boxes. Restriction enzyme 
abbreviations: (E) EcoRV, (X) XbaI, (Sm) SmaI, (S) SacI. (A) Generation of the PDGFRβ KO 
allele. Striped box: PGKneobpA expression cassette. (B) BglII. (B) Generation of the PDGF-
Bret KO allele. Arrowheads: loxP sites (C) Generation of the Runx1-IRES-GFP allele.  
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2.2 Genotyping 
2.2.1 DNA extraction 
Ear clips or small pieces of embryonic tissue (YS or body wall) were placed in 
a solution containing 100µl of Extraction Solution (Sigma, E7526) and 25µl of 
Tissue Preparation Solution (Sigma, T3073). Samples were incubated in a 
shaker at 55oC for 10min, and DNA denatured for 3min at 95oC. After 
denaturation, 100µl of Neutralization Solution B (Sigma, N3910) was added to 
each sample. 
2.2.2 Polymerase chain reaction (PCR) and electrophoresis 
Different PCR reactions were performed for each mouse line as described 
below. PCR products were run at 115V for 1h30 on a 1.5% agarose gel in 
1xTAE buffer (Invitrogen; 15558-026). A molecular weight ladder (EasyLadder 
I; BIO-33046) was added together with the PCR products to determine 
amplicon sizes. From bottom to top, the bands weigh 100, 250, 500, 1000 and 
2000bp. 
2.2.2.1 PDGFRβ KO 
Following DNA extraction, PDGFRβ KO tissues were genotyped to detect both 
the wt and ko sequences, using the primers, PCR reagents and programme 
described below (Table 1-Table 3). WT (114bp) and KO (320bp) bands were 
detected, as shown in Figure 2. 




Fw ACA ATT CCG TGC CGA GTG ACA G 
WT: 114bp 
KO:320bp 
Pdgfrb+/+ Rv AAA AGT ACC AGT GAA ACC TCG CTG 
Pdgfrb-/- Rv ATC AGC CTC GAC TGT GCC TTC TAG 
 






2 µl 10x Coral Load Buffer 
1 µl MgCl2 
0.3 µl HotStarTaqPlus DNA polymerase 
0.1 µl Each primer 
0.5 µl dNTPs (10mM) 
13.9 µl dH2O 
2 µl DNA 
 
Table 3. PCR programme 
Number of cycles Duration Temperature 
1 5min 95 oC 
35 
1min 95 oC 
1min 58 oC 
1min 72 oC 
1 10min 72 oC 
1 +∞ 10 oC 
 
 
Figure 2. PDGFRβ KO genotyping example.  





Following DNA extraction, Runx1-IRES-GFP tissues were genotyped using 
the primers, PCR reagents and programme described below (Table 4). 
Separate PCRs had to be done to detect the wt and gfp sequences, as shown 
in Figure 3. 




Runx1 WT Fw CACCTGTCTCTGCATCGCAGGACT 
WT: 400bp 
Runx1 WT Rv CCATCCGTGACAGATACGCACCTC 
Runx1-GFP Fw GTC CAG GAG CGC ACC ATC TTC TTC 
GFP: 424bp 
Runx1-GFP Rv GTA CAG CTC GTC CAT GCC GAG AGT 
 
Table 5. PCR reaction mix 
Volume/sample Reagent 
10 µl REDExtract-N-Amp PCR Reaction Mix (Sigma, R4775) 
1 µl Each primer 
4 µl dH2O 
4 µl DNA 
 
Table 6. PCR programme 
Number of cycles Duration Temperature 
1 3min 94 oC 
30 
30 sec 94 oC 
45 sec 60 oC 
1min 72 oC 
1 10min 72 oC 





Figure 3. Runx1-IRES-GFP genotyping example.  
Samples (A-H) were run separately to detect the presence of the wt (400bp) and the gfp 
alleles (424bp).  
 
2.2.2.3 PDGFRβ-Cre 
Following DNA extraction, PDGFRβ-Cre tissues were genotyped to detect the 
cre sequence (Figure 4) using the primers, PCR reagents and programme 
described below (Table 7-Table 9).  




PDGFRβ-Cre Fw TGC CAC GAC CAA GTG ACA GCA 
Cre: 324bp 
PDGFRβ-Cre Rv AGA GAC GGA AAT CCA TCG CTC 
 
Table 8. PCR mix used to genotype PDGFRβ-Cre tissues 
Volume/sample Reagent 
5 µl 5x Q Solution 
2.5 µl 10x Coral Load Buffer 
A   B   C    D   E    F   G   H          A   B   C    D   E    F   G   H   
Runx1 wt Runx1 gfp 
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0.5 µl dNTPs (10mM) 
0.4 µl Each primer 
0.2 µl Taq DNA Polymerase 
14.5 µl dH2O 
1.5 µl DNA 
 
Table 9. PCR programme used to genotype PDGFRβ-Cre tissues 
Number of cycles Duration Temperature 
1 5min 94 oC 
29 
30 sec 94 oC 
45 sec 57 oC 
2min 72 oC 
1 10min 72 oC 
1 +∞ 12 oC 
 
 
Figure 4. PDGFRβ-Cre genotyping example.  
The presence of a 324bp band corresponds to the presence of Cre. 
 
2.2.2.4 TdTomato 
Following DNA extraction, TdTomato tissues were genotyped to detect both 
the R26 and tdtomato sequences (Figure 5) using the primers, PCR reagents 
and programme described below (Table 10-Table 12).  
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R26 Fw AAG GGA GCT GCA GTG GAG TA 
R26: 297bp 
R26 Rv CCG AAA ATC TGT GGG AAG TC 
TdTomato Fw CTG TTC CTG TAC GGC ATG G TdTom: 
196bp TdTomato Rv GGC ATT AAA GCA GCG TAT CC 
 
Table 11. PCR mix used to genotype R26;TdTomato tissues 
Volume/sample Reagent 
10 µl REDExtract-N-Amp PCR Reaction Mix (Sigma, R4775) 
1 µl Each primer 
4 µl dH2O 
4 µl DNA 
 
Table 12. PCR programme used to genotype R26;TdTomato tissues 
Number of cycles Duration Temperature 
1 3min 95 oC 
45 
30 sec 95 oC 
30 sec 60 oC 
1min 30sec 72 oC 
1 10min 72 oC 




Figure 5. R26;TdTomato genotyping example.  
The presence of a 196bp band corresponds to the presence of the tdtomato allele, and the 
absence of the wt band (297bp) suggests that these samples come from R26;TdTomato+ 
homozygous mice. Note: Other bands corresponding to a different genotyping were removed 
from between the DNA ladder and the R26;TdTomato samples in this figure. 
 
2.2.2.5 mTmG 
Following DNA extraction, R26;mTmG tissues were genotyped to detect both 
the R26 and mTmG sequences (Figure 6) using the primers, PCR reagents 
and programme described below (Table 13-Table 15).  




R26 Fw CTCTGCTGCCTCCTGGCTTCT 
R26: 330bp 
mTmG: 250bp 
R26 wt Rv CGAGGCGGATCACAAGCAATA 
mTmG Rv TCAATGGGCGGGGGTCGTT 
 
Table 14. PCR mix used to genotype R26;mTmG tissues 
Volume/sample Reagent 
10 µl REDExtract-N-Amp PCR Reaction Mix (Sigma, R4775) 
1 µl Each primer 
4 µl dH2O 




Table 15. PCR programme used to genotype R26;mTmG tissues 
Number of cycles Duration Temperature 
1 3min 94 oC 
35 
30 sec 94 oC 
1min 61 oC 
1min 72 oC 
1 5min 72 oC 
1 +∞ 10 oC 
 
 
Figure 6. R26;mTmG genotyping example.  
The presence of a 250bp band corresponds to the presence of the mTmG allele, and the 




Following DNA extraction, PDGF-Bret tissues were genotyped to detect both 
the wt pdgfb and pdgfbret sequences using the primers, PCR reagents and 
programme described below (Table 16-Table 18). Separate PCRs had to be 
done to detect the wt and pdgfbret sequences, as shown in Figure 7. 





Pdgfb WT Fw CATGCTGCCTTGTAATCCGTT C 
WT: 340bp 
Pdgfb WT Rv CGGCGGATTCTCACCGT 
Pdgfb Ret Fw CTCGGGTGACCATTCGGTAA 
RET:212bp 
Pdgfb Ret Rv TCTAAGTCACAGCCAGGGAGTAGC 
 
Table 17. PCR mix 
Volume/sample Reagent 
10 µl REDExtract-N-Amp PCR Reaction Mix (Sigma, R4775) 
1 µl Each primer 
4 µl dH2O 
4 µl DNA 
 
Table 18. PCR programme 
Number of cycles Duration Temperature 
1 5min 94 oC 
35 
30sec 94 oC 
40sec 63 oC 
1min 72 oC 
1 4min 72 oC 





Figure 7. PDGF-Bret genotyping example.  




2.3.1 Fixation and freezing 
Embryos were dissected, somites counted, and a piece of tissue was taken for 
genotyping. Embryos with their respective placenta and yolk sac were next 
fixed in 2% paraformaldehyde (PFA) for 20-30min on ice, and washed three 
times for 10min with PBS. They were next dehydrated in 20% sucrose/PBS 
and incubated overnight (O/N) at 4oC. On the following day, embryos were 
embedded in OCT, frozen in 100% ethanol cold vapours in dry ice, and stored 
in -20oC until used. Sections 7-10µm thick were cut using a Bright OTF5000 
cryostat and caught onto SuperFrost Ultra Plus slides (Thermo Scientific; 631-
0099). 
2.3.2 Post-fixation and blocking 
On the first day of immunohistochemistry, slides were post-fixed with 100% 
cold methanol for 5-7min at RT and washed three times 5min with PBS.  
2.3.2.1 Avidin/biotin blocking 
Sections to be stained with biotinylated antibodies were blocked with a 
biotin/avidin blocking kit (ThermoFisher Scientific; 004303). Sections were 
incubated with an avidin solution for 15min at RT, washed with PBS for 5min, 
A   B   C   D   E   F   G   H   I    J   K   L         A   B   C   D   E    F   G   H   I    J   K   L   
Pdgfb wt Pdgfbret 
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incubated with a biotin solution for 15 at RT, and washed three times 5min with 
PBS. 
2.3.2.2 Protein block 
All sections were next blocked with 5% goat serum in PBS for 1h or a ready-
to-use protein blocking solution (Spring Bioscience; DPB-125) in a humidified 
container.  
2.3.3 Antibody staining 
Immediately after blocking, sections were incubated with a primary antibody 
(Table 19) O/N at 4oC. On the second day, slides were washed three times 
with PBS and a secondary antibody (Table 20) was added for 1h at room 
temperature (RT) in a dark, humidified chamber. Slides were next washed 
three times for 5min with PBS, and a directly conjugated second primary 
antibody was added for 2h at RT. This antibody was either directly conjugated 
with a fluorochrome or biotinylated (Table 19). Slides were washed again three 
times for 5min in PBS and the sections stained with a biotinylated antibody 
were incubated with streptavidin (FITC or Cy3) (Table 20) for 30min at RT. 
Slides were washed again three times for 5min in PBS, and sections stained 
with DAPI (1:500; Thermofisher Scientific, D1306) for 15min at RT in a dark, 
humidified chamber. Slides were washed again three times 5min in PBS and 
mounted using Fluoromount-G (Southern Biotech, 0100-01). Stained sections 
were imaged using an inverted widefield fluorescence microscope (Zeiss 
Observer) or a Leica SP8 confocal microscope, and pictures analysed with 
Fiji/ImageJ software.  
In certain cases, the second primary antibody used was also unconjugated, 
but raised in different species than the first primary antibody. In these cases, 
the incubation times were the same as for the first primary unconjugated 
antibodies.  













- Millipore ab5320 1:100 








Collagen IV Rabbit Mouse - Bioconnect 2150-1470 1:150 
CD146 488 Rat Mouse ME-9F1 Biolegend 134707 1:100 
αSMA FITC Mouse Mouse 1A4 Sigma F3777 1:100 
αSMA Cy3 Mouse Mouse 1A4 Sigma C6198 1:100 
CD31 
biotinylated 













AF594 Goat Rat Invitrogen A-11007 1:500 
AF594 Goat Rabbit Life Technologies A11012 1:500 
AF488 Goat Rabbit Invitrogen A11008 1:500 
Streptavidin-Cy3 - - Sigma S6402-1ml 1:250 
 
2.3.4 Imaging 
All fluorescent imaging with the exception of PDGFRβ-Cre;mTmG sections 
was performed using an inverted wide field microscope (Axio Observer, Zeiss). 
Pictures were acquired with the Zen Pro blue edition (v2.3) software.  
PDGFRβ-Cre;mTmG sections were imaged using a confocal microscope 
(Leica TCS SP8 5 detectors and 3 detectors) and pictures were acquired using 
the Leica LasX software. All pictures were deconvoluted using Huygens 
Professional (version 19.04) deconvolution wizard, and tiled images (taken 
with a 63x oil objective) were further stitched either simultaneously with 
Huygens deconvolution, or after deconvolution, with FIJI/ImageJ software. 
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Maximum intensity projections were made from 1-10 z-stacks using 
FIJI/ImageJ. All immunohistochemistry and whole-mount pictures are oriented 
with the dorsal aspect of the DA at the top, unless stated otherwise. 
2.4 RNA sequencing and analysis 
All RNA sequencing and analyses used in this thesis were done by our 
collaborators Wilfred van IJcken (Center for Biomics, Department of Cell 
Biology, Erasmus MC University Medical Center, Rotterdam, The 
Netherlands) and Harmen van de Werken (Erasmus Medical Center, Cancer 
Computational Biology Center and Department of Urology, Rotterdam, The 
Netherlands).  
2.4.1 Sequencing 
Cells were sorted and collected directly into 20μl of lysis buffer containing 
Nuclease-free water (Ambion AM9930) 0.2% Triton and 1/20 RNAse inhibitor 
(Thermo Scientific; 10777019). Full-length cDNA was generated from 3.4 ul of 
this cell lysate using the Smarter2 procedure as described (Picelli et al. 2013). 
Sequencing libraries were generated from 500pg of cDNA with Illumina's 
Nextera XT sample prep kit (Illumina Inc., U.S.A) and sequenced for single-
read 43bp on Illumina HiSeq2000 using the Truseq v3 sequencing chemistry 
(Illumina Inc., U.S.A). Reads were aligned against the mouse reference 
genome (mm10) with tophat2 version 2.0.10 [171]. Gene expression values 
were called using Cufflinks (version 2.1.1). 
2.4.2 Analysis 
Raw reads were counted with the summarizeOverlaps function with the 
GENCODE M19 gene annotation [172] using the union mode from the 
Bioconductor [173] Genomic Alignments package (v1.18.1). Genes were 
called differentially expressed after regularized-logarithm transformation using 
DESeq2 (v1.22.2) [174] and setting an absolute fold change of 2. Mean 
centered values were clustered hierarchically with complete linkage using 
Euclidean distances and plotted in a heat map with pheatmap package 
(v1.0.12). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and 
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Genomes (KEGG) gene enrichment analyses were carried out as described 
previously [175] and Reactome Pathway Database analyses were carried out 
with the ReactomePA package (v 1.26.0) [176] ⁠. We used R(v 3.5.3) [177]⁠ for 
statistical analysis and visualization of the data. 
 
2.5 Haematopoietic progenitor assays  
E10 and 11 AGM, PL, head, YS and FL were dissected, dissociated with 
collagenase type I (Sigma, C0130, 0.12% v/v) in PBS (Table 21 andTable 22). 
E10 FL were not taken, as they are too small to dissect, and E11 FL were 
manually dissociated. After digestion, cells were plated as described in Table 
21 and Table 22, in a methylcellulose medium (Methocult GF M3434, Stem 
Cell Technologies Inc.) supplemented with 1%PS, in 35mm petri dishes 
(Falcon 1008). Cells were next incubated at 37oC in an incubator with 5% CO2, 
inside a humidified glass chamber. After 10-12 days, colony-forming units cells 
(CFU-Cs) were counted and distinguished based on their morphology. The 
number of colonies counted was then re-calculated for the total tissue, and the 
Gaussian distribution assessed using the Shapiro-Wilk test. Based on the data 
distribution, a 1-way ANOVA (parametric) followed by a Tukey’s post hoc test, 
or a Kruskal-Wallis (non-parametric) followed by a Dunn’s post hoc test were 
used.  
Table 21. Summary of E10 haematopoietic tissues digestion and seeding conditions.  
This table shows the embryo equivalents (ee) to be seeded in Methocult, the number of 











AGM 1 190 µl 10 µl 45min 2 
Head 0.5 475 µl 25 µl 45min 1 
PL 0.5 475 µl 25 µl 1h15 1 
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YS 0.5 475 µl 25 µl 1h15 1 
 
Table 22. Summary of E11 haematopoietic tissues digestion and seeding conditions.  
This table shows the embryo equivalents seeded in Methocult, the number of dishes, as well 











AGM 0.33 (x3) 190 µl 10 µl 45min 3 
Head 0.33 475 µl 25 µl 45min 1 
PL 0.33 475 µl 25 µl 1h15 1 
YS 0.33 475 µl 25 µl 1h15 1 
FL 0.05 - - - 1 
 
2.6 Transplantations 
2.6.1 Primary transplantations 
2.6.1.1 PDGFRβ KO and PDGF-Bret transplantations 
Single cell suspensions of PDGFRβ and PDGF-Bret E11 AGM cells were 
injected in the tail vein of Ly5.1 heterozygous (CD45.1+CD45.2+) mice. Prior to 
the injections, the recipients were sub-lethally irradiated with 9.4-9.6 Gray (Gy) 
using a Caesium-137 Gammacell 40 Exactor. Irradiations were split in two 
separate doses (half and half), with a 2h break between each dose. AGMs 
were injected together with 20000 BM helper cells from Ly5.1 homozygous 
(CD45.1+CD45.2-) mice. 
2.6.1.2 Bone marrow transplantations 
To harvest the BM, the femur and tibia from both legs was taken, and the tips 
of the bones were carefully cut, until the BM was visible. Using a 1ml syringe 
and a 25G needle, the BM was washed out with PBS/10%FCS/1%PS + 2mM 
EDTA, and centrifuged for 10min at 2000rpm at 4oC. Red blood cells were 
33 
 
lysed by re-suspending the pellets in an ammonium chloride solution (Stem 
Cell Technologies, 07850) for 12min (6min, mix, 6min). Cells were next 
washed and centrifuged. For primary BM transplantations, cells were re-
suspended in 5ml PBS/10%FCS/1%PS + 2mM EDTA. 10µl of cells were taken 
for counting and diluted with Trypan Blue (Corning, 25-900-CI). Cells were 
counted using either a Bürker-Türk or a Bürker haemocytometer. To calculate 
the total number of cells using the Bürker-Türk (16 squares were counted), the 
formula below was used: 
𝐶𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑝𝑒𝑟 𝑚𝑙 = # 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 ×
25
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× 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 × 104 
To calculate the total number of cells using the Bürker haemocytometer (25 
squares were counted in at least 2 different positions and the average was 
calculated), the formula below was used: 
𝐶𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑝𝑒𝑟 𝑚𝑙 = # 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 × 104 
Between 0.5x106 and 1x106 cells were injected into primary recipients. For 
secondary BM transplantations, harvested BM cells were equally divided and 
injected into 2 recipients. 
2.6.1.3 PDGFRβ-Cre;TdTomato transplantations 
Sorted Tomato+ and Tomato- E11 AGMs, E14 FLs and adult BMs (see section 
2.8.2) were injected in the tail vein of Ly5.1 heterozygous (CD45.1+CD45.2+) 
mice. Prior to the injections, the recipients were sub-lethally irradiated with 9 
Gy using a Caesium-137 IBL 637 C irradiator (type GSR-CS137/D). 
Irradiations were split in two separate doses (half and half), with a 2h break 
between each dose. Sorted cells were injected together with 200000 spleen 
cells from Ly5.1 homozygous mice. These cells were injected in another animal 
facility, hence the difference in the helper cells injected and the irradiation dose 
compared to other transplantations. 
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2.6.2 Peripheral blood analysis 
Blood was taken from the submandibular vein, 1 and 4 months after 
transplantation and analysed by flow cytometry to assess the level of donor 
chimerism (% of CD45.1- CD45.2+ cells) (Table 23). At 4 months, lymphoid and 
myeloid reconstitution was also assessed with CD4, CD8, CD11b, CD19 and 
Gr1 staining (Table 23). To perform the analysis, red blood cells were lysed 
with an ammonium chloride solution (Stem Cell Technologies, 07850) for 
12min (6min, mix, 6min) at RT, and incubated for 30min at 4oC in the dark, with 
the antibody mix below:  
Table 23. Antibodies used for peripheral blood flow cytometry analysis 




CD45.1 FITC A20 Biolegend 110706 1:1000 
CD45.2 Pacific Blue 104 Biolegend 109820 1:1000 
CD4 PE H129.19 Biolegend 130310 1:5000 
CD8a PE 53-6.7 Biolegend 100708 1:500 
CD11b/Mac-1 APC M1/70 Biolegend 101212 1:1000 
CD19 APC-Cy7 6D5 Biolegend 115530 1:1000 
Gr-1/Ly-6G/C PE-Cy7 RB6-8C5 Biolegend 108416 1:2000 
 
Cells were next washed, re-suspended in 300µl of 2% FCS in PBS and 
analysed by flow cytometry. Sytox AAD (Thermofisher, S10349) was used to 
detect dead cells.  
2.6.3 Secondary transplantations 
Following the 4 months analysis, successfully reconstituted mice (>4% donor 
chimerism) were sacrificed, and the total BM from both legs was harvested to 
perform secondary transplantations. Red blood cells were lysed as described 
above (section 2.6.1.2), and the total number of BM cells injected into two sub-
lethally irradiated Ly5.1 heterozygous recipients. Blood from secondary 
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recipients was analysed after 1 and 4 months as described above (section 
2.6.2). 
2.7 Flow cytometry 
All flow cytometry analyses in this thesis started with the selection of single live 
cells. Cells were first separated from debris or clumps of cells by forward vs. 
side scatter (SSC-A, FSC-A). Single cells were next separated from doublets 
using FSC-H vs. FSC-A correlation, and live cells were selected by the 
absence of Sytox staining. Occasionally, Sytox 7AAD (Thermofisher; S10349) 
was replaced with other live/dead markers, such as DAPI (Thermofisher 
Scientific; D1306), Zombie NIR (Biolegend; 423105), or Sytox Green 
(Thermofisher Scientific; S34860)  
2.7.1 AGM cell populations analyses 
AGMs were dissected and digested in collagenase type I (Sigma, C0130, 
0.12% v/v), washed with PBS/2%FCS/1%PS (FACS buffer) and centrifuged at 
2000rpm for 10min. Pellets were re-suspended in one of the antibody mixes 
described below (Table 24 andTable 25) for 30min at 4ºC. Cells were washed 
again, centrifuged, and pellets re-suspended in 300µl FACS buffer. All cells 
were analysed using BD LSR Fortessa with 4 lasers, with the exception of 
AGMs stained with αSMA, which were analysed using an ACEA NovoCyte 
flow cytometer.  
2.7.1.1 PDGF-Bret 
PDGF-Bret AGMs were stained with the antibody cocktail described below 
(Table 24).  
Table 24. Flow cytometry antibodies used for PDGFR-Bret mutant AGM analyses.  
Antibody Clone Supplier Cat. Number Dilution 
NG2 488 - Millipore ab5320a4 1:100 




BD Pharmingen 550994 1:400 
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cKit BV421 2B8 BD Horizon 562609 1:500 
PDGFRα APC - Biolegend 135908 1:100 
Sytox AAD - Thermofisher S10349 1:10000 
 
2.7.1.2 PDGFRβ;Runx1-IRES-GFP 
PDGFRβ;Runx1-GFP mutant AGMs were stained with the antibodies below 
(Table 25). 
Table 25. Flow cytometry antubodies used for PDGFRβ;Runx1-GFP mutant AGM 
analyses. 
Antibody Clone Supplier Cat. Number Dilution 
NG2 Cy3 - Millipore ab5320c3 1:100 
PDGFRβ APC APB5 eBioscience 17-1402-82 1:250 
CD31 PE-Cy7 - eBioscience 25-0311-82 1:4000 
CD45 PerCpCy5.5 30-F11 (RUO) BD 
Pharmingen 
550994 1:400 
cKit BV421 2B8 BD Horizon 562609 1:500 
Sytox AAD - Thermofisher S10349 1:10000 
 
2.7.1.3 PDGFRβ analysis in all haematopoietic organs 
PDGFRβ expression was assessed in E8-E11 AGM, head, FL, PL and YS by 
staining single cell suspensions with PDGFRβ APC antibody (1:250; 
eBioscience; 17-1402-82). As it is difficult to dissect the FL before E10, the 
whole body (excluding the organs, head, PL and YS) was analysed at E8 and 
E9.   
2.7.1.4 αSMA expression analysis 
Following collagenase digestion, E10.5 PDGFRβ mutant AGM cells were 
stained with Zombie NIR (Biolegend; 423105) for 30min at 4ºC. Samples were 
next washed and permeabilised in 200µl of 4% PFA for 30min at 4ºC, washed, 
and further permeabilised with 0.5% Triton X100 (Sigma; T8787-100ML) in 
PBS for 30min at 4ºC. αSMA-Cy3 (1:200; Sigma; C6198-.2ml) was next added 
to each sample and incubated for 30min at 4ºC in the dark, after which they 
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were washed, centrifuged, re-suspended in 300µl of FACS buffer and 
analysed using an ACEA NovoCyte flow cytometer. 
2.7.2 LSK and LSK-SLAM analysis 
BM cells from PDGF-Bret mutant, PDGFRβ-Cre;TdTomato and BL6 adult mice 
were harvested and red blood cells were lysed as described above (section 
2.6.1.2). Samples were washed with PBS/10%FCS/1%PS/2mM EDTA and 
centrifuged for 10min at 2000rpm. Pellets were re-suspended in an antibody 
mix containing haematopoietic lineage biotinylated antibodies (Lin) (Table 26) 
diluted in BM FACS buffer (PBS/2%FCS/1%PS/2mM EDTA) and incubated for 
30min at 4ºC. Cells were next washed and centrifuged, and pellets were 
resuspended in a second antibody mix containing directly conjugated 
antibodies, and Streptavidin-PerCp to detect all Lin biotinylated antibodies 
(Table 27), and incubated for 30min at 4ºC. BM cells from PDGFRβ-
Cre;TdTomato were not stained with CD48 nor CD150. Cells were washed 
and resuspended in 1ml of BM FACS buffer and analysed with a BD LSR 
Fortessa flow cytometer with 4 lasers. DAPI (1:500; Thermofisher Scientific, 
D1306) was used to distinguish between live and dead cells. Results were 
analysed with FlowJo X software. 







CD4 H129.19 BD Biosciences 553648 1:1600 
CD5 53-7.3 BD Biosciences 553018 1:800 
CD8a  53-6.7 BD Biosciences 553028 1:800 
CD11b / Mac-1   M1/70 BD Biosciences 553309 1:200 
CD45R / B220 RA3-6B2 BD Biosciences 553086 1:200 
Gr-1 / Ly-6G/C RB6-8C5  BD Biosciences 553125 1:100 
Ter119 TER-119 BD Biosciences 553672 1:50 
 
Table 27. Antibodies used for LSK and LSK-SLAM analyses.  
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CD117 / c-kit APC 2B8 BioLegend 105812 1:200 
Sca-1 / Ly-6A/E APC-
Cy7 
E13-161.7 BioLegend 122514 1:200 
CD48 / SLAMf2 PE HM48-1 BioLegend 103406 1:800 




BioLegend 115914 1:200 
Streptavidin PerCp - BioLegend 405213 1:200 
 
2.8 Fluorescence-activated cell sorting (FACS) 
AGMs were dissected from E10 and E11 embryos, digested in collagenase 
type I (Sigma, C0130, 0.12% v/v) in PBS for 45 min at 37oC, mechanically 
dissociated into single cell suspensions and washed with 10%FCS in PBS.  
2.8.1 Sorting of PDGFRβ+ and PDGFRβ- cells 
Cells to be sorted based on PDGFRβ expression were incubated for 30 min at 
4oC in the dark with PDGFRβ PE antibody (1:250; eBioscience, 136006). E11 
cells were additionally stained with cKit BV421 antibody (1:500; BD Horizon; 
562609) to enrich in HSPCs, as it has been reported that all progenitors are 
cKit+ [32]. Following the incubation, cells were washed twice in PBS/FCS and 
sorted using a BD FACSAria Fusion flow cytometer. Sorted cells were next 
seeded in methylcellulose, and colonies were counted 10-12 days later.  
2.8.2 Sorting of Tomato+ and Tomato- cells 
2.8.2.1 AGM 
Cells to be sorted based on Tomato expression were incubated for 30 min at 
4oC in the dark with cKit BV421 antibody (1:500; BD Horizon; 562609), washed 
twice with FACS buffer and sorted using a BD FACSAria Fusion flow 
cytometer. Sorted cells were next seeded in methylcellulose and colonies were 
counted 10-12 days later.  
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2.8.2.2 Foetal liver and bone marrow 
E14 FL and adult BMs were dissected and dissociated in PBS/FCS as 
described above, and single live cells were sorted based on Tomato 
expression using a BD FACSAria Fusion flow cytometer. Sorted cells were 
next seeded in methylcellulose or injected in sub-lethally irradiated recipients. 
2.9 3D whole-mount immunostaining 
Embryos were separated from the PL and YS, fixed in 2% PFA for 20min on 
ice and washed 3 times for 10min with PBS. A piece of tissue was taken for 
genotyping prior to the fixation. Embryos were next dehydrated twice with 50% 
methanol in PBS for 10min at 4oC, twice with 75% methanol in PBS for 10min 
at 4oC and once with 100% methanol for 10min at 4oC. Embryos were then 
stored in 100% methanol at -20oC until used. Before use, embryos were further 
dissected, removing the head, limb buds, somites, and one side of the body 
wall. They were then rehydrated in 75% methanol and in 50% methanol for 
10min each at 4oC. To reduce unspecific antibody binding, they were next 
blocked using a biotin/avidin blocking kit (ThermoFisher Scientific; 004303). 
Embryos were immersed in 1ml of PBS containing 3 drops of the avidin 
solution for 15min at RT, washed for 5min in PBS, re-immersed in 1ml of PBS 
containing 3 drops of the biotin solution, and washed 3 times 5min with PBS. 
They were additionally blocked with BSA/PBS-MT (10% (w/v) BSA, 1% (w/v) 
of skim milk and 0.4% (v/v) of TritonX in PBS) for 1h at 4oC. Embryos were 
next incubated O/N at 4oC on a rocking platform with the first primary antibody 
either unconjugated cKit (1:500; BD Bioscience; 553352), or unconjugated 
NG2 (1:500; Millipore; ab5320). On the second day, they were washed 4 times 
for 30 min to 2h with PBS-MT and incubated overnight at 4oC with either 
Alexa647 (1:2500; Invitrogen; A21472) as a secondary antibody for cKit or 
Alexa647 (1:2500; Invitrogen; A21245) as a secondary antibody for NG2.  On 
the third day, embryos were washed 4 times for 30 min to 2h and incubated 
with the second and third primary antibodies, αSMA FITC (1:500; Sigma; 
F3777) and CD31 biotin (1:500 BD Pharmingen; 553371) overnight at 4oC. On 
the fourth day, embryos were washed as in the previous days and incubated 
with Streptavidin Cy3 (1:2500; Sigma; S6402) overnight at 4oC. On the fifth 
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day, embryos were washed 4 times with PBS-MT and rinsed with PBST (0.4% 
TritonX in PBS) for 20min at 4oC. They were next dehydrated in methanol at 
4oC (50% methanol for 10min followed by 100% methanol for 10min). Embryos 
were then transferred to glass containers where the methanol was replaced by 
50% BABB/methanol (1 part benzyl alcohol with 2 parts benzyl benzoate in 
methanol) 4 times. 50% BABB/methanol was then replaced with 100% BABB 
until the embryos became completely clear. Embryos were next mounted on a 





Chapter 3 Characterisation of the HSC-
generating microenvironment 
3.1 Introduction 
Endothelial cells in the ventral aspect of the dorsal aorta rely upon signals from 
the sub-aortic mesenchyme to initiate the haematopoietic programme and 
generate HSCs. In the chick embryo, it was shown that by preventing the 
migration of the splanchnic mesoderm before it develops into the subaortic 
mesenchyme leads to the absence of Runx1 expression by ECs and 
subsequent formation of haematopoietic clusters [97]. This suggests that sub-
aortic cells derived from the splanchnic mesoderm are required to initiate the 
haematopoietic programme in the dorsal aorta. In addition, several studies 
have shown that several murine stromal cell lines obtained from midgestation 
AGM support haematopoiesis and express HSC-supportive genes 
[125,156,178], suggesting that mesenchymal stromal cells can act as a niche 
for HSPCs. However, the ability to support haematopoiesis varied greatly 
depending on the stromal cell line, suggesting an inherent heterogeneity in 
AGM stromal cells. Taken together, these data suggest that the AGM 
microenvironment could play a role in both HSC specification and as a niche 
for HSCs. Characterising the microenvironment surrounding the midgestation 
DA both phenotypically and genetically, should provide a better insight on the 
cell types and signals required for HSC generation and maintenance in the 
AGM.  
3.2 Hypothesis and aims 
3.2.1 Hypothesis 
The midgestation aortic microenvironment contains mesenchymal stromal 
cells that act as a niche for HSC generation.  
3.2.2 Aims 
- Phenotypic characterisation of mesenchymal stromal cell populations 
surrounding the aorta at the time of HSC generation. 
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- Establish and validate an isolation protocol for the populations defined 
above. 






3.3.1 Three phenotypically distinct perivascular cell 
populations surround the midgestation dorsal aorta 
 
To understand the composition of the AGM microenvironment during HSC 
generation, immunohistochemistry was performed on C57BL6 E11 
cryosections, using different marker combinations to identify and characterise 
perivascular mesenchymal stromal cells that surround the dorsal aorta (Figure 
8 andFigure 16). The DA is composed of a layer of CD31+ endothelial cells, 
surrounded by mesenchymal stromal cells and sided by the cardinal veins 
(CVs). On the dorsal side of the DA, the notochord (NC) can be distinguished 
by its morphology (Figure 8). 
 
 
Figure 8. E11 dorsal aorta.  
Cross-section of a BL6 E11 mouse embryo, showing the dorsal aorta (DA) sided by the 
cardinal veins (CVs). The notochord (NC) is located on the dorsal side of the DA. CD31 (red) 
was used to mark the endothelium and DAPI (blue) to mark the nuclei. Scale bar: 100µm. 
 
To characterise the cells surrounding the dorsal aorta, immunohistochemistry 
using previously described pericyte/vascular smooth muscle cell (vSMC) 
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markers such as NG2, αSMA, PDGFRβ and CD146 was performed. Antibody 
specificity against these markers was provided by the manufacturers, 
confirmed in several publications and previously tested in the lab. Negative 
controls to test the specificity and background fluorescence levels of the 
secondary antibodies were performed (Figure 9). Sections were stained with 
only the secondary antibody and DAPI. No unspecific staining and very little 
background fluorescence was detected for each secondary antibody used in 
this study (Figure 9). 
 
Figure 9. Negative controls.  
Immunohistochemistry on frozen BL6 E11 sections stained with secondary antibodies only. 
(A) Goat anti-rat AF594, (B) Goat anti-rabbit AF594, (C) Goat anti-rabbit AF488, (D) 
Streptavidin-Cy3. Nuclei were counterstained with DAPI (blue). The dashed line delineates the 
DA. Scale bar: 100µm. 
 
Immunostainings with NG2 and CD31 show one or more layers of NG2+ 
CD31- cells surrounding and in close contact with the CD31+ endothelium 
(Figure 10). The notochord is also surrounded by NG2+ CD31- cells (Figure 
10). NG2 expression along the notochord varies, depending on the area in 
which the section was taken (Figure 10,Figure 11 and Figure 14). As expected, 




Figure 10. NG2+ cells surround the E11 DA.  
Immunohistochemistry on a frozen E11 BL6 section, showing a layer of NG2+ cells (green) 
surrounding and in close contact with a layer of CD31+ cells (red). NG2+ CD31- cells are also 
found around the notochord. The bottom panel shows a higher magnification of the top panel. 
Nuclei were counterstained with DAPI (blue). Scale bars: upper panel: 100µm; bottom panel: 
10µm.   
 
All NG2+ cells surrounding the DA were found to express αSMA, with the 
exception of NG2+ cells around the notochord (Figure 11). No NG2 expression 
could be detected around the cardinal veins, whereas some αSMA+ cells are 
present (Figure 11). 
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Figure 11. NG2+ perivascular cells co-express αSMA.  
Immunohistochemistry on a frozen E11 C57BL6 section, showing that all NG2+ (green) cells 
surrounding the DA co-express αSMA (red). In contrast, NG2+ cells around the NC do not 
express αSMA. The bottom panel shows a higher magnification of the top panel. Nuclei were 
counterstained with DAPI (blue). Scale bars: upper panel: 100µm; bottom panel: 10µm. 
 
As pericytes and vascular smooth muscle cells are embedded in a basement 
membrane, immunostainings with collagen IV were performed (Figure 12). 
NG2+ cells were found to be embedded in Collagen IV, with the exception of 
some NG2+ cells closer to the endothelium that only show collagen IV staining 
on the abluminal side, especially on the ventral side of the DA (Figure 12, 
middle panel). On the dorsal aspect of the DA, most NG2+ cells are fully 
embedded in collagen IV (Figure 12, bottom panel). The additional layers of 
NG2+ on the ventral aspect of the DA (Figure 12, middle panel) suggest that 
the section was either taken in close proximity to the vitelline artery, as shown 
by 3D whole mount staining in Chapter  4 (Figure 34B), or that the embryo was 




Figure 12. NG2+ perivascular cells are embedded in collagen IV.  
Immunohistochemistry on a frozen E11 BL6 section, showing that NG2+ cells (red) 
surrounding the DA are embedded in a collagen IV+ basement membrane (green). The middle 
panel shows a higher magnification of the ventral aspect of the DA. Arrows: NG2+ cells fully 
embedded in collagen IV; asterisks: NG2+ cells partially embedded in collagen IV. The bottom 
panel shows a higher magnification of the dorsal aspect of the DA, and the beginning of an 
intersomitic vessel (ISV). Arrowheads: NG2+ cells with collagen IV on the luminal side. Nuclei 
were counterstained with DAPI (blue). Scale bars: upper panel: 100µm; middle and bottom 
panels: 10µm.   
 
Immunostainings with PDGFRβ and CD31 showed that CD31+ ECs, as 
expected, do not express PDGFRβ (Figure 13) [148]. Several layers of 
PDGFRβ+ cells were detected around the DA and cardinal veins (CVs), and 




Figure 13. Several layers of PDGFRβ+ cells surround the aortic endothelium. 
Immunohistochemistry on a frozen E11 C57BL6 section, showing several layers of PDGFRβ+ 
cells surrounding and in close contact with a layer of CD31+ (red) cells. PDGFRβ+ cells are 
also found surrounding the cardinal veins (CV). The bottom panel shows a higher 
magnification of the top panel. Nuclei were counterstained with DAPI (blue). Scale bars: upper 
panel: 100µm; bottom panel: 10µm.  
 
To better understand the distribution of NG2 and PDGFRβ expressing cells, 
sections were stained with both markers (Figure 14). All NG2+ cells 
surrounding the DA co-express PDGFRβ, but not all PDGFRβ+ cells express 
NG2 (Figure 14). A few layers of NG2+ PDGFRβ+ cells are found next to the 
endothelium, and several layers of NG2- PDGFRβ+ cells are found further 
from the endothelium and adjacent to NG2+ PDGFRβ+ cells (Figure 14). 






Figure 14. NG2+ cells surrounding the DA co-express PDGFRβ.  
Immunohistochemistry on a BL6 E11 cryosection, showing that all NG2+ cells (red) 
surrounding the DA express PDGFRβ (green), but not all PDGFRβ+ cells express NG2. The 
bottom panel shows a higher magnification of the top panel. Nuclei were counterstained with 
DAPI (blue). Scale bars: upper panel: 100µm; bottom panel: 10µm. 
 
CD146 is a marker for a subset of pericytes and endothelial cells in the mouse 
AGM [179]. Immunostainings against CD146 and CD31 confirmed that most 
ECs express CD146 (Figure 15; arrows), and few ECs (CD31+) do not express 
CD146 (Figure 15; arrowheads). CD146 expression was also found in 
perivascular cells adjacent to the endothelium (Figure 15; asterisks).  
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Figure 15. A subset of ECs express CD146.  
Immunohistochemistry on frozen BL6 E11 sections. Most ECs express CD146 (green) and 
CD31 (red) (arrows), while some do not express CD146 (arrowheads). CD31- perivascular 
cells express CD146 (asterisks). The bottom panel shows a higher magnification of the top 
panel. Nuclei were counterstained with DAPI (blue). Scale bars: upper panel: 100µm; bottom 
panel: 10µm. 
 
To further distinguish between CD146+ ECs and CD146+ perivascular cells, 
sections were co-stained with αSMA (Figure 16). As expected, on the luminal 
part of the DA, where the endothelium is located, CD146+ cells do not express 
αSMA (Figure 16; arrows). Adjacent to the endothelium, most cells co-express 
CD146 and αSMA. αSMA+ CD146- cells were also found next to the double 




Figure 16. A subset of pericytes express CD146.  
Immunohistochemistry on a BL6 E11 cryosection showing CD146 (green) and αSMA (red) 
expression. CD146+ αSMA- ECs can be found closest to the lumen of the DA (arrows), 
followed by CD146+ αSMA+ perivascular cells. Adjacent to these cells, some CD146- αSMA+ 
cells can be found (asterisks). The bottom panel shows a higher magnification of the top panel. 
Nuclei were counterstained with DAPI (blue). Scale bars: upper panel: 100µm; bottom panel: 
10µm. 
 
Based on these data, we identified three phenotypically distinct perivascular 
cell populations surrounding the DA at the time of HSC generation: 
pericytes/vascular smooth muscle cells (PCs/vSMCs), in close contact with the 
endothelium, which express NG2, αSMA and PDGFRβ; sub-pericytes/sub-
vascular smooth muscle cells (sub-PCs/sub-vSMCs), a few layers of cells 
surrounding the pericytes and CVs, which express PDGFRβ but are negative 
for NG2 and αSMA; and the stroma, a population of cells that does not express 
any of these markers (Figure 17). For simplicity, PCs/vSMCs and sub-




Figure 17. Scheme depicting the three perivascular cell populations surrounding the 
midgestation dorsal aorta.  
A layer of CD31+ endothelial cells (ECs) is surrounded by NG2+ PDGFRβ+ pericytes (PCs) 
that are embedded in a Coll IV+ basement membrane. Several layers of NG2- PDGFRβ+ 
perivascular cells (sub-PCs) surround the pericytes, and are surrounded by the remaining 
stroma (NG2- PDGFRβ-). 
 
3.3.2 Pericytes are found surrounding the DA at E10 but not 
before. 
Some studies suggest that HSC specification starts between E8.5 and E10.5 
[56]. As the DA is still growing and remodelling, E9 and E10 DAs were also 
characterised by immunohistochemistry. At E9, aortic ECs express CD31 
(Figure 18). No NG2+ cells are found surrounding the paired aortae at E9 
(Figure 18, upper panel), but are present around the fused aorta at E10 (Figure 





Figure 18. NG2 is expressed around the DA at E10 but not at E9.  
Immunohistochemistry on BL6 E9 (upper panel) and E10 (bottom panel) cryosections showing 
NG2 (green) and CD31 (red) expression. No NG2+ cells are found at E9, whilst they are 
present around the DA endothelium at E10. Nuclei are counterstained with DAPI (blue). NT: 
neural tube. Scale bars: 100µm. 
 
PDGFRβ expression was detected around the paired aortae at E9 and 
surrounding the fused DA and cardinal veins at E10 (Figure 19). These results 
were further confirmed by flow cytometry (Chapter 4, figure 30). 
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Figure 19. PDGFRβ is expressed around the DA at E9 and E10.  
Immunohistochemistry on BL6 E9 (upper panel) and E10 (bottom panel) cryosections showing 
PDGFRβ (green) and CD31 (red) expression. PDGFRβ+ cells are found around the paired 
aortae at E9, and the fused aorta and cardinal veins at E10. Nuclei are counterstained with 
DAPI (blue). Scale bars: 100µm. 
 
CD146 expression was detected in ECs lining the DA (αSMA- cells closer to 
the lumen), and a few perivascular cells (αSMA+) at both E9 and E10 (Figure 
20). At E9, the paired aortae are not surrounded by αSMA+ cells, but a few 
αSMA+ cells can be found close to the endothelium and only between the 
paired aortae (Figure 20, upper panel). At E10, the DA is fully surrounded by 




Figure 20. CD146 and αSMA are expressed around the DA at E9 and E10. 
Immunohistochemistry on BL6 E9 (upper panel) and E10 (bottom panel) cryosections showing 
CD146 (green) and αSMA (red) expression. Few αSMA+ cells can be detected at E9, between 
the paired aortae, but fully surround the DA at E10. The endothelium and some αSMA+ cells 
express CD146 at both stages. Nuclei are counterstained with DAPI (blue). Scale bars: 
100µm. 
 
Although no NG2 expression was detected around the paired aortae at E9 
(Figure 18, upper panel) and few cells express αSMA (Figure 20, upper panel), 
a collagen IV+ basement membrane is already present around the paired 
aortae at this stage (Figure 21, upper panel).  
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Figure 21. Collagen IV is present around the DA at E9 and E10.  
Immunohistochemistry on BL6 E9 (upper panel) and E10 (bottom panel) cryosections showing 
collagen IV (green) and CD31 (red) expression. Collagen IV fully surrounds the CD31+ 
endothelium at both E9 and E10. Nuclei are counterstained with DAPI (blue). Scale bars: 
100µm. 
 
These data suggest that the same three perivascular cell populations shown 
to surround the DA at E11 (Figure 17) are already present at E10. E9 paired 
aortae on the other hand, have no NG2 expression and only a few αSMA+ 
cells. Interestingly, a collagen IV basement membrane is already present 
around the aortae at E9, even in the absence of αSMA+ cells, which suggests 
that either ECs or PC precursors are responsible for its production and 
deposition. 
 
3.3.3 Pericytes, sub-pericytes and stromal cells surrounding 
the midgestation DA are genetically distinct 
To understand whether the three perivascular stromal cell populations 
identified above are genetically different, bulk RNA sequencing was 
performed. Upon doublets and dead cell exclusion, E11 AGM cells were sorted 
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based on the absence of the haematopoietic and endothelial cell markers cKit, 
CD45 and CD31, and on the presence or absence of NG2 and PDGFRβ, as 
shown in Figure 22. Although immunohistochemistry characterisation of AGM 
stromal cells was not performed using CD45 and cKit, stromal cells, were 
sorted based on their absence to exclude all haematopoietic cells. A population 
of NG2+ PDGFRβ- cells were also found by flow cytometry, in line with 
immunohistochemistry data showing NG2+ PDGFRβ- cells surrounding the 
notochord (Figure 10,Figure 11 andFigure 22). 
 
 
Figure 22. Gating strategy used to sort midgestation PCs, sub-PCs and stroma.  
Gating strategy used to sort the three different perivascular cell populations. Haematopoietic 
and endothelial markers were negatively selected within the total population of single live cells. 
PCs (CD31- cKit- CD45- NG2+ PDGFRβ+), Sub-PCs (CD31- cKit- CD45- NG2- PDGFRβ+) 
and stroma (CD31- cKit- CD45- NG2- PDGFRβ-) were sorted and bulk RNA sequencing was 
performed. 
 
As samples were sorted directly into a lysis buffer for RNA sequencing, it was 
not possible to confirm the purity of each sample after the sort. However, 
population purity was assessed after RNA sequencing, by plotting the FPKM 
(Fragments Per Kilobase of transcript per Million mapped reads) values of the 
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genes used for the sorting. The purity was generally good, with slight Pdgfrb 
expression in the stroma (Figure 23). This contamination of PDGFRβ+ cells in 
the stromal fraction might be due to the fact that there is no clear separation 
between PDGFRβ+ and PDGFRβ- cells and the lack of stringency in the gating 
strategy used to sort both populations (Figure 22). 
 
Figure 23. Post-RNA sequencing purity check.  
Fragments Per Kilobase of transcript per Million mapped reads (FPKM) values of the markers 
used to sort each population of perivascular cells after RNA sequencing. The gene names for 
NG2, PDGFRβ, CD31, cKit and CD45 are Cspg4, Pdgfrb, Pecam1, Kit and Ptprc, respectively.  
 
Clustering analysis was performed by our collaborator H. van de Werken, and 
PCs were found to be transcriptomically more distant than the sub-PCs and 
stroma, which cluster closer together (Figure 24A). This was confirmed by PCA 
analysis (Figure 24B). Dataset comparisons found 1029 differentially 
expressed genes (DEG) between all three populations (Figure 24C; all DEG 
are listed in appendix table 1). PCs and sub-PCs have a total of 791 DEGs, 
PCs and stromal cells have a total of 668 DEG, while sub-PCs and stroma only 
differ by 10 genes (Figure 24C). Comparisons between datasets are listed in 
appendix table 2, and DEGs common to two datasets can be found in the first 
table of each tab. A table containing all FPKM values can be found in appendix 





Figure 24. PCs, Sub-PCs and stroma are genetically distinct.  
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(A) Heatmap showing the top 50 differentially expressed genes and clustering between 
perivascular cell populations. (B)  Principal component analysis (PCA) of gene expression, 
showing the two principal variance components. (C) Venn diagram showing numbers of 
differentially expressed genes (DEG) in comparisons of PCs vs Sub-PCs, PCs vs stroma and 
stroma vs sub-PCs. Total DEG is 1029 (see appendix tables 1 and 2 for gene lists). Note: 
these graphs were made by our collaborator H. van de Werken and adapted to this thesis by 
me. 
 
3.3.4 Purified PCs from the midgestation AGM express 
expected genes  
The isolation of perivascular cells described above was next validated by RNA 
sequencing analysis. An enrichment in several known pericyte-specific genes 
was found, as expected, in the PC population (Figure 25). Genes such as 
pdgfrb, NG2 (Cspg4) [180], CD146 (Mcam) [118,180], nestin (nes) [181], leptin 
receptor (lepr) [114], desmin (Des) and αSMA (Acta2) [182] were upregulated 
in the PC population compared to sub-PCs and stroma. Other perivascular cell 
marker expression, such as Tbx18 [183] and Gli1 [184] was higher in sub-




Figure 25. Pericyte-specific gene expression in E11 perivascular cells.  
FPKM values for known PC/vSMC genes between the three perivascular cell populations, 
obtained by RNA sequencing. FPKM values were extracted from appendix table 3.  
 
3.3.5 Midgestation PCs are enriched in genes involved in 
basement membrane formation  
As expected, PCs were also found to express high levels of genes involved in 
basement membrane formation, such as calponin 1 (Cnn1), Collagens 
(Col1a1, 4a1, 4a2), vimentin (Vim), fibronectin 1 (Fn1) and procollagen C-
endopeptidase enhancer (Pcolce) [185,186] (Figure 26). 
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Figure 26. Basement membrane formation genes.  
FPKM values for genes known to be involved in basement membrane formation between the 
three perivascular cell populations, obtained by RNA sequencing. FPKM values were 
extracted from appendix table 3.  
 
3.3.6 DA midgestation pericytes are enriched in known HSC-
niche genes 
As perivascular cells were shown to support haematopoiesis in the adult BM, 
HSC-niche gene expression, reviewed in [107] was assessed. We found that 
PCs are enriched in several niche genes, such as Cxcl12 [118,120,187], 
Jagged1 (Jag1) [117,118], N-Cadherin (N-Cadh) [118] (Figure 27). Other HSC-
niche genes such as Angiopoietin1 (Ang1) [118,120] and Kit ligand or Scf (Kitl) 
[118,119] are higher in sub-pericytes and stroma than in pericytes (Figure 27), 
suggesting that these populations might also play a role in AGM 
haematopoiesis. Lastly, some genes that were also described in pericytes that 
support haematopoiesis in the BM, such as Adrenoceptor Beta 1 (Adrb3) [122] 
and osteopontin 3 (Spp1) [114,123] are lowly expressed in all three 





Figure 27. Adult BM HSC-niche genes.  
FPKM values for known adult BM HSC-niche genes expressed by perivascular cells, obtained 
by RNA sequencing. FPKM values were extracted from appendix table 3.  
 
3.4 Discussion 
The main goal of this chapter was to characterise the heterogeneous HSC-
generating niche both phenotypically and genetically, and to establish an 
isolation protocol for further analysis.  
3.4.1 The midgestation HSC-generating niche is 
heterogeneous 
HSC generation relies on signals from the AGM microenvironment. Stromal 
cells surrounding the dorsal aorta were shown to be required for HSC 
specification and generation [97], and can potentially be important for the 
support and maintenance of HSCs generated in this region [125,156,178]. This 
microenvironment is however heterogeneous, and little is known about the 
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types of cells present and the signals they produce. Understanding all the 
factors and cell types required for HSC generation in the AGM could provide 
important cues needed to generate and maintain HSCs in culture.  
The main objective of this Chapter was to characterise the HSC-generating 
microenvironment, with a focus on the stromal cells surrounding the dorsal 
aorta. Three phenotypically distinct populations of perivascular stromal cells 
were defined at E10 and E11 based on immunohistochemistry by differential 
perivascular cell marker expression (NG2, αSMA and PDGFRβ) and absence 
of the endothelial marker CD31.  
Pericytes (PCs) were defined as cells expressing NG2, αSMA and PDGFRβ, 
in close contact with the endothelium and embedded in a collagen IV+ 
basement membrane. Adjacent to PCs, a few layers of sub-PCs were shown 
to express PDGFRβ, but not NG2 nor αSMA. Surrounding sub-PCs, stromal 
cells that do not express any of these markers were found. NG2 and αSMA 
co-expression by cells surrounding the DA endothelium was previously 
reported between E10 and E14 [141], and more recently, PDGFRβ expression 
in these cells was also described [179]. Although PDGFRβ is also expressed 
around the cardinal veins, NG2+ αSMA+ PDGFRβ+ PCs can only be found 
around the DA. Interestingly, PDGFRβ was expressed in more cell layers on 
the aortic floor, where HSCs are born, suggesting a potential role for PDGFRβ 
signalling in AGM haematopoiesis. Whether NG2+ PDGFRβ+ PCs exist in 
other haematopoietic organs, such as the head, placenta, yolk sac and foetal 
liver during the two waves of embryonic haematopoietic cell generation 
remains to be determined.  
The embryonic dorsal aorta is an organ undergoing constant growth and 
remodelling, and therefore, perivascular cells are continuously changing. 
Although the three perivascular cell populations described above were present 
at both E10 and E11 (time of HSC generation in the DA), at E9, NG2 
expression was absent, and only a few cells were found to express αSMA, as 
previously reported  [140,141]. After E11, the number of layers of PC/vSMCs 
surrounding the aorta increases as the aorta develops into a more mature 
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blood vessel [179]. Furthermore, although these three populations were 
defined based on NG2, αSMA and PDGFRβ, it is important to bear in mind 
that they can be even more heterogeneous. For instance, CD146, a membrane 
glycoprotein that mediates the interaction between pericytes and ECs [188], 
was found to be expressed by a subset of PCs, suggesting that PCs could be 
even further separated based on CD146 expression. CD146+NG2+ 
expression around the embryonic DA has been previously reported to mark 
immature vSMCs that gradually lose CD146 expression as they mature into 
aortic vSMCs [179]. Due to CD146 expression dynamics between E10 and 
E11, NG2 and PDGFRβ were preferentially used as markers to separate 
pericytes from sub-pericytes. It would be interesting however, to further 
separate PCs into CD146+ and CD146- at E10 and E11, and perform RNA 
sequencing to understand which, if not both populations play a role in HSC 
generation and/or maintenance.  
A population of NG2+ cells was also detected around the notochord, which is 
not surprising, since NG2 (also known as neural/glial antigen 2) is a 
proteoglycan mainly found in cells of the developing and adult nervous system 
[189]. These cells did not express PDGFRβ, allowing for the separation 
between NG2+ cells around the notochord and those surrounding the dorsal 
aorta.  
3.4.2 RNA sequencing analysis 
Based on the expression of NG2 and PDGFRβ, and the absence of the 
haematopoietic and endothelial markers CD45, cKit and CD31, all three 
populations of perivascular cells were sorted for bulk RNA sequencing.  
Clustering analysis found that PCs are transcriptomically more distinct than 
sub-PCs and stromal cells, with 791 DEG between PCs and Sub-PCs and 668 
between PCs and stroma. Sub-PCs and stroma were only different by 10 
genes. However, it is very likely that this is due to contamination of the stromal 
fraction by PDGFRβ+ cells, as seen by some Pdgfrb expression in the stromal 
fraction. This is probably due to the lack of stringency used on the gating 
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strategy to sort PDGFRβ+ and PDGFRβ- cells, as there is no clear separation 
between the two populations. PDGFRβ expression appears to be gradual 
according to flow cytometry and immunohistochemistry data, with higher 
PDGFRβ expression around the DA and CVs. Therefore, the differences in 
gene expression profile obtained between the two populations might be higher 
than what was obtained in this experiment. In addition, only one replicate was 
used for RNA sequencing, and therefore these data are only suggestive, and 
need to be confirmed with additional biological replicates.  
3.4.2.1 Expected genes are found to be expressed in PCs  
RNA sequencing data found several pericyte/vSMC-specific genes 
upregulated in the PC population, such as Pdgfrb (PDGFRβ), Cspg4 (NG2), 
Mcam (CD146) and Acta2 (αSMA), confirming our immunohistochemistry data 
and sorting strategy. Other pericyte/vSMC genes such as Nestin and Desmin 
were also upregulated (Figure 25). More recently, Gli1 [184] and Tbx18 [183] 
were proposed as novel pericyte markers in adult mice, but their expression 
was not specific to the E11 PC population, suggesting that they are not 
markers for AGM pericytes/vSMCs, but rather, for perivascular stromal cells 
around the AGM in general.  
3.4.2.2 E11 PCs are enriched in basement membrane formation genes 
One of the defining aspects of pericytes is their embedding in a basement 
membrane which is shared with the endothelium. The interaction between 
these two cell types was shown to regulate basement membrane assembly, 
which is produced by both pericytes and endothelial cells [185,186]. RNA 
sequencing data show that E11 PCs are highly enriched in genes involved in 
basement membrane formation (Figure 26). The presence of collagen IV was 
found surrounding the paired aortae of E9 embryos (Figure 21), before the 
onset of NG2, and was present in places where αSMA expression was absent, 
suggesting that it is either produced and deposited by ECs or PDGFRβ+ 
precursors of PCs that are found around the E9 aortae.  
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3.4.2.3 PCs are enriched in known HSC-supportive genes 
In the adult BM of both mouse and human, HSCs maintenance and 
differentiation is controlled by the BM microenvironment [114–116], in 
particular by different populations of perivascular stromal cells, including 
pericytes. Interestingly, E11 PCs were enriched in several genes that have 
been described in various populations of perivascular cells that support BM 
haematopoiesis (reviewed in [107]).  
For instance, CD146+ perivascular cells with HSC-niche activity in vivo and ex 
vivo were described around sinusoids and microvessels in the human adult 
[117,118,124] and foetal BM [117], as well as in white adipose tissue [117]. 
They were initially described and isolated in 2007 from human BM sinusoids, 
and shown to have the capacity to establish a heterotopic haematopoietic 
microenvironment when transplanted into immunodeficient mice [118]. These 
cells were shown to be osteoprogenitors, as they formed ossicles containing 
donor-derived bone and sinusoids upon transplantation, and recruited host-
derived endothelial and haematopoietic cells. Adult BM CD146+ cells also 
expressed other pericyte markers such as Cspg4, Acta2, Pdgfrb, basement 
membrane formation genes, such as Col1a1 and Col1a2, and haematopoietic 
niche-related transcripts, such as Cxcl12 (CXC chemokine ligand, also known 
as SDF1), Jagged-1 (Notch ligand), Cdh2 (N-cadherin) and Scf (Kit ligand or 
Kitl). These molecules have been reported to maintain murine BM HSCs both 
in vivo and in vitro [119–121]. Our RNA sequencing data show that these 
transcripts are upregulated mainly in the PC population, (Figure 26 andFigure 
27, Appendix table 3), with the exception of Kitl that was higher in the stroma 
than in the other two populations (but expressed in all three). Kitl expression 
has been previously reported in the entire sub-aortic mesenchyme and ECs, 
as well as in YS ECs and perivascular cells [155]. Kitl deletion was shown to 
reduce the numbers of YS EMP progenitors, as well as to impair the maturation 
and survival of pre-HSCs in the AGM [155]. Together, these data suggest that 
NG2- PDGFRβ- stromal cells might play a role in the maturation and 
maintenance of AGM HSCs via the expression of Kitl. This needs to be 
confirmed by selectively deleting Kitl in the different populations of perivascular 
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stromal cells. In addition, these CD146+ BM cells were shown to activate 
Notch signalling in HSPCs [118] via the expression of one of its ligands 
JAGGED-1, crucial for HSC generation in the AGM [190]. CXCL12 binds to 
CXCR4 in HSCs and promotes their homing to the BM and quiescence. 
Perivascular cells expressing high levels of Cxcl12 (also known as CXCL12-
abundant reticular cells, or CAR cells) were shown to be associated with 
quiescent HSCs in mouse BM sinusoids and endosteum [120,191]. CD146+ 
pericytes found in human white adipose tissue were found to differentiate into 
adipocytes and osteoblasts, and were shown to support HSC activity in co-
cultures with cord blood HSCs through Jagged1/Notch signalling [117]. CD45+ 
cells taken from these co-cultures were shown to repopulate primary and 
secondary recipient immunodeficient mice. CD146+ pericytes were also found 
in foetal BM [117], and together with adipose tissue pericytes, they express 
Nestin, Cxcl12, and Lepr, which are markers that have been found in 
perivascular cells that have HSC niche activity in the BM [115,120,122]. These 
genes were upregulated in E11 AGM PCs (Figure 27), while Lepr was 
expressed by all three populations of perivascular cells (Figure 25). LepR+ 
cells were described around murine BM sinusoids, and were shown to be 
required for the maintenance of BM HSPCs and their retention in the BM [116], 
by secreting Scf [187].  
Another HSC-niche population described in the adult BM with similar 
characteristics as E11 PCs were Nestin+ neural crest-derived MSCs found 
around arterioles near HSCs, adrenergic nerve fibres [114,115,122,123], and 
human foetal BM [123]. They were shown to express high levels of Cxcl12, 
Adrb3 and Agpt1 and support haematopoiesis [122]. These cells have a similar 
distribution to CAR cells [122]. Besides Cxcl12 expression, E11 PCs were also 
enriched in Agpt1 and Nestin (Figure 25 andFigure 27). HSC numbers in the 
BM were shown to be reduced upon the depletion of Nestin+ cells, and their 
homing ability was also impaired when transplanted into Nestin+ depleted mice 
[122]. Within the Nestin+ MSC population, around 30% were shown to express 
NG2. Interestingly, deletion of Cxcl12 from BM arteriolar NG2+ cells led to the 
reduction of HSCs in the BM, as well as a change in localisation [187], 
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suggesting that Nestin+ NG2+ MSCs are required for HSC maintenance. HSC-
supporting capacity of the different perivascular cell populations needs to be 
further assessed, either by co-culturing AGM HSPCs with each population, or 
by deleting known HSC-niche genes in each population.  
In addition to being components of the BM HSC niche, most of these 
populations showed MSC differentiation potential (osteogenic, adipogenic and 
chondrogenic). Interestingly, E11 AGM stromal cells were also shown to have 
MSC potential when cultured under different MSC conditions [127]. Other 
haematopoietic organs such as the YS, liver, umbilical and vitelline arteries 
were unable to differentiate into any of the 3 lineages [127]. It would be 
interesting to test the MSC potential of each individual perivascular stromal cell 
population described in this Chapter with differentiation assays in vitro.  
Although the n number of this experiment was low (n=1), the data obtained by 
RNA sequencing was consistent with several other studies, both in embryonic 
and adult haematopoietic tissues, and the expression of some of these genes 
was confirmed by immunohistochemistry and flow cytometry. 
Overall, several populations of perivascular cells with HSC niche activity have 
been described in the BM, many of which partially overlap. Most of the genes 
expressed by these cells were found to be upregulated in E11 AGM PCs, or 
expressed in all perivascular cell subsets identified in this Chapter, suggesting 
a putative role for the aortic mesenchyme in the support of HSC generation 
and/or maintenance in the AGM. This possible role needs to be further tested 
in vitro and in vivo, either by co-culturing PCs, sub-PCs and stroma together 
with HSPCs, or by specifically deleting certain genes such as Kitl or Cxcl12 for 
example in perivascular cells of the AGM.  
3.4.3 Nomenclature 
Pericytes and vSMCs are called mural cells that function as regulators of 
vascular stability and blood vessel homeostasis. By definition, pericytes are 
cells surrounding microvessels (capillaries, postcapillary venules and terminal 
arterioles), although this has recently been questioned by the detection of 
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pericyte-like cells surrounding larger vessels [192]. The second characteristic 
defining pericytes, is that they are embedded in a basement membrane shared 
with endothelial cells. Pericytes and endothelial cells contact each other via 
openings in the basement membrane. It is however difficult to determine 
whether the basement membrane is shared by both pericytes and ECs during 
embryonic development, as the basement membrane is still being synthesised 
[193], and without the use of electron microscopy [194]. VSMCs on the other 
hand, surround larger vessels and arteries, are not in direct cell-cell contact 
with ECs, but are separated from the endothelium by a basement membrane, 
and in larger arteries, by the tunica intima [193]. In arterioles and venules, 
mural cells have intermediate properties between PCs and vSMCs. It has been 
suggested that vSMCs and PCs represent phenotypic variants of a continuous 
population of mural cells sharing the same lineage. This variation would reflect 
different subspecialisations in accordance with their location in the vascular 
system [195], as well a common origin [193,196] 
Our study focuses on the embryonic aorta, where vascular remodelling takes 
place prior to maturation. At this stage, NG2+ αSMA+ PDGFRβ+ cells 
described in this chapter are similar to pericytes found in small vessels. 
However, due to αSMA expression and their localisation around a large vessel, 
it is possible that they are developing vSMCs. As the DA develops, additional 
αSMA+ layers can be found surrounding the endothelium from E12 onwards 
until it becomes a fully mature artery [179]. However, only NG2+ CD146+ cells 
surrounding the DA were shown to be aortic vSMC precursors (although 
morphologically similar to pericytes), and give rise to mature vSMCs 
surrounding the aorta. As only a subset of E11 PCs express CD146, it is 
unclear whether CD146- PCs also give rise to vSMCs in the adult aorta. The 
distinction between pericytes and vSMCs is often difficult, as there are 
currently no specific pericyte and vascular smooth muscle markers unique to 
each population. In addition, most markers have been described in the adult 
and developing brain, or at later stages in development, making it more difficult 
to determine the cell types present in the E10-E11 DA.  
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The main reason we called NG2+ PDGFRβ+ perivascular cells as pericytes, 
was due to their enrichment in HSC-niche genes described in pericytes and 
other perivascular cells in the adult BM. There have been no reports so far on 
vSMC support in haematopoiesis at any stage of development nor in the adult.  
3.4.4 Conclusions and future work 
To briefly summarise this Chapter, three phenotypically and genetically distinct 
populations of perivascular cells were detected around the midgestation DA: 
PCs, sub-PCs and stroma. All three were enriched in HSC-niche genes 
previously described in adult BM perivascular cells with MSC activity that are 
required for the maintenance of BM HSCs, suggesting a potential role in the 
haematopoietic AGM niche. To understand whether midgestation perivascular 
stromal cells support haematopoiesis, co-culture experiments of each 
perivascular population with HSCs need to be performed. Additionally, it would 
be interesting to test the differentiation potential of each population in the three 
MSC lineages, to better establish the relationship between AGM and BM 
perivascular cells, and link them to their HSC-support ability. Ideally, single cell 
RNA sequencing should be performed in E10 and E11 pericytes, to further 
dissect the heterogeneity of the HSC-generating niche. As HSC generation 
might not be exclusive to the AGM, it would also be interesting to determine 










In the previous chapter, PDGFRβ expression was detected in mesenchymal 
stromal cells surrounding the midgestation dorsal aorta, and PDGFRβ+ cells, 
in particular pericytes, were enriched in HSC-supportive genes previously 
described in the adult BM [107].  
It has been suggested that during blood vessel formation and maturation, 
pericytes and vascular smooth muscle cells are first induced in a PDGF-
B/PDGFRβ independent manner and subsequently require PDGFRβ 
signalling to migrate and proliferate as blood vessels develop [182]. 
Pericyte/vSMC induction is dependent on TGFβ signalling in mice [197], and 
more recently, Ando and colleagues showed that zebrafish peri-arterial naïve 
mesenchymal cells are induced by Notch signalling to become PDGFRβ+ 
mural cells [198]. Pericytes are then recruited along the developing blood 
vessel via PDGF-B/PDGFRβ signalling. ECs secrete PDGF-B, which binds to 
the extracellular matrix forming a gradient that allows pericyte/vSMC 
recruitment to the endothelial wall [158,199]. Morpholino knockdown of pdgfrb 
or dominant-negative pdgfrb expression in zebrafish was shown to reduce 
hematopoietic stem and progenitor cell formation in zebrafish, and PDGF-B 
overexpression enhanced HSPC numbers in the AGM [149]. In line with these 
data, it was further shown that PDGF signalling contributes to the HSC 
specification niche by directing neural crest cells to physically associate with 
HSC precursors and initiate the definitive haematopoietic programme in 
zebrafish [148]. Taken together, these data suggest a role for PDGFRβ in HSC 
specification and/or generation/maintenance. To understand whether 
PDGFRβ signalling plays a role in murine AGM haematopoiesis, we used a 
constitutive KO mouse model for PDGFRβ. PDGFRβ KO mice die at birth with 
haemorrhages, and show an abnormal kidney development due to the 
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absence of mesangial cells [157]. Some haematological defects such as 
thrombocytopenia and anaemia were also observed in these embryos. 
Interestingly, their overall development appears to be normal until E16 
[142,157]. 
4.2 Hypothesis and aims 
4.2.1 Hypothesis 
PDGFRβ signalling is required for HSC generation in the dorsal aorta. 
4.2.2 Aims 
- Determine whether PDGFRβ deletion affects AGM haematopoiesis. 
- Determine whether midgestation HSPCs are affected by PDGFRβ 
deletion. 
- Understand whether PDGFRβ deletion affects pericyte recruitment to 
the dorsal aorta. 
- Trace PDGFRβ-derived cells in haematopoietic organs. 
4.3 Results 
4.3.1 Validation of PDGFRβ KO mouse model 
To validate PDGFRβ KO mouse model, immunohistochemistry was performed 
on E11 AGM cryosections (Figure 28). As expected, PDGFRβ expression was 
absent in PDGFRβ KO embryos, whereas several layers of PDGFRβ+ cells 




Figure 28. Validation of PDGFRβ KO mouse model.  
Immunohistochemistry showing PDGFRβ+ cells (green) surrounding CD31+ endothelium 
(red) on an E11 WT embryo, and the absence of PDGFRβ+ cells in an E11 KO embryo. Scale 
bar: 20µm. 
 
4.3.2 PDGFRβ deletion affects E11 AGM HSPCs 
To understand whether PDGFRβ deletion affects midgestation 
haematopoiesis, haematopoietic progenitor assays (CFU-Cs) were performed 
on E10 and E11 mutant AGM cells. Full AGMs were dissociated and cultured 
in a methylcellulose medium containing factors that promote the growth of the 
HSPCs present in the tissue. After 10-12 days, colonies were counted and 
distinguished based on their morphology as shown below (Figure 29).  
 
Figure 29. Haematopoietic progenitor assays.  
Representative pictures of the different types of colonies found in haematopoietic progenitor 
assays after 10-12 days. BFU-E: burst-forming unit erythroid; CFU-G: colony-forming unit-
granulocyte; CFU-M: colony-forming unit-macrophage; CFU-GM: colony-forming unit-
granulocyte and macrophage; CFU-GEMM: colony-forming unit-granulocyte, erythrocyte, 





No differences were found in the numbers of colonies at E10 (Figure 30A, 
Table 28). Interestingly, at E11, a significant decrease in the total number of 
colonies was found between WT, HET and KO embryos (Figure 30B, Table 
29). The largest difference in colony numbers was found between WT and KO 
embryos, for all types of colonies (Table 29). Between WT and HET embryos, 
no differences were found in CFU-M, CFU-GM and the most immature CFU-
GEMM colonies (Table 29). With the exception of the total number of colonies, 
there were no significant differences in individual colony numbers between 
HET and KO embryos (Table 29). These data suggest that PDGFRβ is 
required for E11 AGM haematopoiesis, but not before.  
 
Figure 30. Haematopoietic progenitor assays in PDGFRβ mutant midgestation AGMs. 
Number of colonies (CFU-C) per PDGFRβ WT, HET and KO (A) E10 (29-34sp) and (B) E11 
(43-45sp) AGMs. See Table 28 (E10) and Table 29 (E11) for complete CFU-C results. 
 
The decline in HSPCs in the AGM in PDGFRβ KO embryos could be due to 
deficient production of HSPCs in other haematopoietic organs in the absence 
of PDGFRβ. To assess whether PDGFRβ is expressed in these organs, flow 
cytometry analysis of PDGFRβ was performed in the head, body/FL, PL and 
YS, from E8 to E11 (Figure 31A). PDGFRβ+ cells were detected in all organs 
(Figure 31). Due to the difficulty of dissecting the AGM and FL before E10, the 
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whole body, excluding the head, PL and YS was analysed. PDGFRβ was 
expressed in over 40% of the cells in the body/AGM and head between E8 and 
E11. Peak expression was detected in the body and AGM at E9-E10 
(60.2%±2.31 and 55.3%±2.33, respectively), the head and the YS at E10 
(52.4%±1.13 and 32.93%±4.83, respectively). The highest expression of 
PDGFRβ in the PL was found at E8 (12.67%±1.30). Foetal and maternal 
placenta were analysed together at this stage due to the difficulty in separating 
them, and therefore it is unclear whether these PDGFRβ+ cells are embryonic, 
maternal, or both. From E9 to E11, less than 5% of the cells in the placenta 
express PDGFRβ. At E10, 11.03%±1.44 of FL cells express PDGFRβ, and 
22.87%±5.45 at E11 (Figure 31B).  
 
Figure 31. PDGFRβ is expressed in all E8-E11 haematopoietic organs.  
(A) Example of the flow cytometry gating strategy used to analyse PDGFRβ expression in all 
organs. The percentage of PDGFRβ+ cells is assessed from single live cells (upper panel).  
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All plots shown are from E10 analyses. (B) Percentage of PDGFRβ+ cells in different BL6 
haematopoietic organs from E8 to E11, determined by flow cytometry. E10 AGM, n=6; E11 
AGM, n=7; n=3 for all the other organs and developmental stages. 
 
As PDGFRβ expression was detected in all other haematopoietic organs, 
haematopoietic progenitor assays were also performed for E10 and E11 head, 
FL, PL and YS (Figure 32). Although no significant differences were detected 
in any of these organs (Figure 32, Table 28 andTable 29), there seems to be 
a decrease in the total number of progenitors in the E10 KO head, compared 
to both WT and HET, as well as an increase in progenitors in the E10 PL 
(Figure 32, Table 28). At E11 (Figure 32, Table 29), no significant differences 
were found in CFU-C numbers in the head, PL, YS nor foetal liver (FL), with 
the exception of granulocyte progenitors (CFU-G) in the head (with a 
significant decrease between WT and HET, and HET and KO embryos), CFU-
GM in the PL (with a significant decrease between WT and HET embryos), 
and in BFU-E in the YS (between WT and KO embryos). A significant 
difference was also detected in the number of macrophages in the FL, but the 





Figure 32. Haematopoietic progenitor assays in PDGFRβ mutant haematopoietic 
organs at midgestation.  
CFU-C numbers per PDGFRβ WT, HET and KO (A) E10 (29-34sp) and (B) E11 (40-45sp) 
head, placenta (PL) and yolk sac (YS). See tables Table 28 (E10) and Table 29 (E11) for 
complete CFU-C results. 
 
Table 28. Summary of CFU-C data for PDGFRβ WT, HET and KO E10 haematopoietic 
organs.  
Haematopoietic progenitor assays were performed for E10 (29-34sp) AGM, head, foetal liver, 
placenta and yolk sac. The number of CFU-C per tissue (mean ± SD), fold changes of CFU-
C numbers between WT, Het and KO mice, the statistical tests used, p values and multiple 





Table 29. Summary of CFU-C data for PDGFRβ WT, HET and KO E11 haematopoietic 
organs.  
Haematopoietic progenitor assays were performed for E11 (40-45sp) AGM, head, foetal liver, 
placenta and yolk sac. The number of CFU-C per tissue (mean ± SD), fold changes of CFU-
C numbers between WT, Het and KO mice, the statistical tests used, p values and multiple 
comparison tests are shown here. Significant differences are indicated with asterisks: *: 







Although HSPCs are affected in the E11 AGM, transplantations need to be 
performed to understand whether HSCs are affected. For this, E11 WT, HET 
and KO AGMs were transplanted into sub-lethally irradiated recipients, 
together with BM helper cells (Figure 33A). To detect and distinguish cells from 
donors and recipients, the Ly5.1 (CD45.1) and Ly5.2 (CD45.2) isoform system 
was used. AGM cells express the Ly5.2 isoform, BM helper cells express 
Ly5.1, and the recipients’ blood cells express both Ly.1 and Ly.2 on their 
surface (Figure 33B).  
 
Figure 33. AGM transplantations and peripheral blood analysis.  
(A) Schematic representation of the transplantation procedure for mutant AGMs. AGMs 
(Ly5.2) cells were injected together with Ly5.1 homozygous BM helper cells into sub-lethally 
irradiated Ly5.1/.2 heterozygous recipients. (B) Gating strategy used to assess the level of 
reconstitution 4 months after transplantation. After selecting for single live cells, the 
percentage of donor cells could be assessed by the expression of Ly5.2 and absence of Ly5.1. 
From Ly5.1- Ly5.2+ donor cells, lymphoid (CD4/8+ T cells, CD19+ B cells) and myeloid 
(CD11b+ and Gr1) reconstitution was also assessed.  
 
Peripheral blood was analysed for the presence of donor Ly5.1- Ly5.2+ cells 
at 4 months, and mice were considered positively reconstituted, when the 
percentage of donor chimerism was above 4%. Although the number of 
reconstituted mice was generally low after 4 months in the control group (1 
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mouse reconstituted/ 5 transplanted) (Figure 34), KO AGMs failed to 
reconstitute primary recipients, suggesting that the deletion of PDGFRβ affects 
HSCs. Lineage reconstitution was assessed among positively reconstituted 
mice, and no differences were found in lineage reconstitution potential (not 
shown). 
 
Figure 34. Blood reconstitution analysis 16 weeks after primary transplantations. 
Analysis of long-term reconstitution potential 4 months after E11 AGM transplantation into sub-
lethally irradiated recipients. Each data point represents one mouse injected with 1 embryo 
equivalent. Mice are reconstituted when >4% donor cells are found in the host peripheral 
blood. Numbers of reconstituted mice/number of transplanted mice are given for each group. 
 
4.3.3 PDGFRβ deletion alters pericyte phenotype but does 
not affect DA integrity 
 
One possible explanation for the reduction in HSPC numbers in the AGM of 
PDGFRβ KO embryos is a leakage in the dorsal aorta (DA), as PDGF-
B/PDGFRβ signalling is required for blood vessel integrity via the recruitment 
of pericytes to the endothelial wall [182]. No morphological differences were 
observed between WT and KO whole E10.5 embryos (Figure 35A). Whole-
mount immunostainings for CD31, αSMA, NG2 and cKit were next performed 
on E10.5 WT and KO DAs (Figure 35B, C). The integrity of the DA was not 
impaired, as seen by normal aortic morphology and CD31 expression in the 
KO compared to the WT (Figure 35B, C). NG2+ αSMA+ perivascular cells are 
still present around the endothelium, suggesting that PDGF-B/PDGFRβ 
signalling is not required for pericyte recruitment to the DA. Interestingly, NG2 
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expression is lower in the KO DA compared to the WT, while αSMA expression 
is higher, especially near the vitelline artery (VA). These results suggest that 
pericytes are differentiating towards more mature vSMCs and possibly 
proliferating (Figure 35B). Although cKit+ haematopoietic clusters were 
detected in both WT and KO DAs, clusters appear to be larger in the KO. 
Importantly, no leakage of cKit+ cells from the DA was observed in KO 
embryos (Figure 35C). 
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Figure 35. PDGFRβ deletion leads to phenotypic changes in pericytes.  
(A) Brightfield images of WT and KO E10.5 embryos. (B, C) Confocal images of whole-mount 
immunostainings of WT and KO E10.5 DAs stained with (B) NG2 (cyan), αSMA (yellow) and 
CD31 (magenta), and (C) cKit (cyan) and CD31 (magenta). ISV: intersomitic vessels; NT: 




Immunohistochemistry was also performed on PDGFRβ WT and KO 
cryosections, to see whether PDGFRβ deletion leads to changes in the 
presence or cell distribution of the different populations of perivascular cells 
(Figure 36-Figure 38). Confirming the 3D-whole mount immunostaining data 
(Figure 35B), NG2+ cells are still present around the CD31+ endothelium in 
both PDGFRβ WT and KO DAs, and NG2 expression is lower in the KO than 
in the WT. NG2 expression around the notochord appears to be unchanged 
(Figure 36). 
 
Figure 36. NG2 expression is reduced in PDGFRβ KO embryos.  
Immunohistochemistry on PDGFRβ WT and KO E11 cryosections, stained with NG2 (green) 
and CD31 (red). Nuclei were counterstained with DAPI. ISV: intersomitic vessel; NC: 
notochord. The dorsal side of the DA is on the right, and the ventral on the left. Scale bars: 
100µm.  
 
Immunostaining with αSMA and NG2 in E11 PDGFRβ WT and KO embryos 
shows a higher number of αSMA+ cell layers around the aorta in KO embryos 




Figure 37. Increase in the number of αSMA+ layers surrounding the DA of PDGFRβ KO 
embryos.  
Immunohistochemistry on PDGFRβ WT and KO E11 cryosections stained with NG2 (green) 
and αSMA (red). Nuclei were counterstained with DAPI. ISV: intersomitic vessel; NC: 
notochord. The dorsal side of the DA is on the right, and the ventral on the left. 
 
No differences were found in CD146 expression between PDGFRβ WT and 
KO E11 embryos, with both the endothelial and pericyte layers expressing 




Figure 38. CD146+ cells distribution is not affected by PDGFRβ deletion.  
Immunohistochemistry on PDGFRβ WT and KO E11 cryosections, stained with CD146 
(green) and CD31 (red). Nuclei were counterstained with DAPI. ISV: intersomitic vessel; NC: 
notochord. 
 
4.3.4 Characterisation of AGM cell populations in PDGFRβ 
mutants by flow cytometry. 
Flow cytometry analyses were next performed on PDGFRβ;Runx1-IRES-GFP 
E10 and E11 AGMs, to determine whether the percentages of different cell 
populations in the AGM, including HECs (ECs expressing Runx1) were altered 
upon PDGFRβ deletion (Figure 39-Figure 42). Single live cells were analysed 
for the expression of different markers such as αSMA, NG2, CD31, CD45, cKit, 
PDGFRβ and Runx1-GFP at E10 (Figure 39) and E11 (Figure 40). At E10, no 
significant differences were found in αSMA expression between PDGFRβ WT 
and KO embryos, although an increase can be observed in the KO (Figure 
39A). In addition, a significant decrease in NG2 expression was detected in 
NG2+ cells (Figure 39B). Together, these results support the observations 
made in the E10.5 whole-mounts (Figure 39B). As expected, no PDGFRβ+ 
cells were found in KO embryos. In addition, no differences were found in 





Figure 39. Flow cytometry analysis of single AGM cell populations in E10 PDGFRβ 
mutants.  
(A) Percentage of αSMA+ single viable cells in PDGFRβ WT(n=4), HET (n=7), KO (n=5) E10 
(31-34sp) AGMs (B) Percentage of NG2+, CD31+, CD45+, cKit+, PDGFRβ+ and Runx1-
GFP+ single viable cells in WT (n=6), HET (n=17) and KO (n=8) PDGFRβ;Runx1-GFP per 
E10 AGM (33-36sp). Error bars: SD. * p<0.05; ** p<0.01; **** p<0.0001. 
 
At E11, no differences were found in any single population of cells, with the 
exception of PDGFRβ (Figure 40). The decrease in NG2+ cells at E10 




Figure 40. Flow cytometry analysis of NG2, CD31, cKit, PDGFRβ and Runx1-GFP 
populations from mutant E11 PDGFRβ;Runx1-GFP AGMs.  
Percentage of NG2, CD31, CD45, cKit, PDGFRβ and Runx1-GFP single viable cells in WT 
(n=5), HET (n=7) and KO (n=7) PDGFRβ;Runx1-GFP per E11 AGM (43-46sp). Error bars: 
SD. *** p<0.001; **** p<0.0001. 
 
To determine whether ECs and HECs were affected by the deletion of 
PDGFRβ, flow cytometric analysis was performed on E10 and E11 
PDGFRβ;Runx1-GFP AGMs (Figure 41). The percentage of ECs was 
determined by the exclusion of cKit+ and CD45+ cells, and expression of CD31 
(Figure 41A). CD31+ ECs were next gated on Runx1+ cells to obtain the 
percentage of HECs (Figure 41A). No differences were found at either stage 
in the percentage of ECs (Figure 41B, C). However, at E10, but not at E11, the 
percentage of HECs was significantly reduced in KO embryos (Figure 41B, C). 
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Figure 41. HECs are significantly decreased in PDGFRβ KO embryos.  
(A) Gating strategy used to analyse ECs (CD31+ CD45- cKit-) and HECs (CD31+ Runx1+ 
CD45- cKit-) AGM cells by flow cytometry, based on the absence of cKit and CD45 expression. 
(B,C) Percentage of ECs and HECs in mutant PDGFRβ;Runx1-GFP AGMs at (B) E10 (33-
36sp) and (C) E11 (43-46sp). Error bars: SD. * p<0.05. 
 
HSPCs were next analysed by selecting single CD31+ cKit+ cells. No changes 
in the percentages of HSPCs and Runx1+ HSPCs were found in 




Figure 42. Percentages of AGM HSPCs and Runx1+ HSPCs are not affected in PDGFRβ 
KO mutants.  
(A) Gating strategy used to analyse HSPCs (CD31+ cKit+) and Runx1+ HSPCs (CD31+ cKit+ 
Runx1+) AGM cells by flow cytometry. (B,C) Percentage of HSPCs and Runx1+ HSPCs in 
mutant PDGFRβ;Runx1-GFP AGMs at (B) E10 (33-36sp) and (C) E11 (43-46sp). Error bars: 
SD.  
 
As some stromal cells also express Runx1, we analysed the percentages of 
Runx1 expressing cells in PDGFRβ mutant embryos at E10 and E11 (Figure 
43). Stromal cells were analysed based on the absence of the endothelial and 
hematopoietic markers CD31, cKit and CD45 (Figure 43A). The percentage of 
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stromal cells was not altered upon PDGFRβ deletion at either time points 
(Figure 43A, B). At E10, no differences were observed in the percentage of 
Runx1-expressing stromal cells (Figure 43A), but at E11 a significant decrease 
was detected in KO embryos compared to WT (Figure 43B). These data 
suggest PDGFRβ deletion also affects Runx1 expression in the stroma, in 
addition to HECs.   
 
Figure 43. Runx1 expression in stromal cells is reduced in PDGFRβ KO mutants.  
(A) Gating strategy used to analyse AGM stromal cells by flow cytometry, based on the 
absence of cKit, CD45 and CD31 expression. (B,C) Percentage of stromal cells and Runx1+ 
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stromal cells in mutant PDGFRβ;Runx1-GFP AGMs at (B) E10 (33-36sp) and (C) E11 (43-
46sp). Error bars: SD. * p<0.05. 
 
4.3.5 Functional AGM HSPCs do not express PDGFRβ 
Whether midgestation functional HSPCs express PDGFRβ is not known. E10 
and E11 BL6 AGMs were sorted into PDGFRβ+ and PDGFRβ- populations 
(Figure 44A, C) and seeded in methylcellulose. Post-sort purity checks were 
conducted, and all samples were found to be highly purified (Figure 44B, D) 
 
Figure 44. Gating strategy and post-sort purity of PDGFRβ+ and PDGFRβ- E10 and E11 
AGM cells.  
(A) Representative FACS plots of PDGFRβ+ and PDGFRβ- E10 AGM sorts. Gates are based 
on the unstained sample and PDGFRβ staining. (B) Post-sort purity of PDGFRβ+ and 
PDGFRβ- cells shows negligible contamination of PDGFRβ+ in the PDGFRβ- population and 
vice-versa. (C) Representative FACS plots of PDGFRβ+ and PDGFRβ- E11 AGM sorts. Gates 
are based on the unstained sample and cKit and PDGFRβ staining. (D) Post-sort purity of 
PDGFRβ+ and PDGFRβ- cells shows no contamination in either sorted population. (B, D) 
Numbers in the gates correspond to the percentage of the total number of cells found inside 
each gate. 
 
Haematopoietic progenitor activity was only detected in the PDGFRβ- 
population at both stages (Figure 45), suggesting that functional HSPCs do 
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not express PDGFRβ and therefore, the deletion of PDGFRβ does not directly 
affect HSPC function.  
 
Figure 45. PDGFRβ+ E10 and E11 AGM cells are not haematopoietic.  
CFU-C numbers of sorted BL6 PDGFRβ- and PDGFRβ+ cells at E10 (26-33sp; n=8) and E11 
(40-45sp; n=6). Error bars: SD; ****: p<0.0001. 
 
4.3.6 PDGFRβ-Cre marks a subset of HSPC precursors 
 
Another possibility to explain the phenotype observed in PDGFRβ KO embryos 
is that HSPCs derive from PDGFRβ precursors. To test this, PDGFRβ-Cre 
mice were crossed with R26;TdTomato mice [161]. Upon PDGFRβ 
expression, Cre recombinase excises a stop cassette, allowing for TdTomato 
expression. Thus, PDGFRβ+ cells and their progeny will express TdTomato. 
E10 and E11 AGM cells from PDGFRβ-Cre;TdTomato were sorted into 
Tomato+ and Tomato- populations, and seeded in methylcellulose (Figure 
46A). As all AGM HSPCs were reported to express cKit [32], Tomato- cells 
were enriched in cKit expression (Figure 46A). No contamination was detected 




Figure 46. Gating strategy and post-sort purity of cKit+Tomato- and Tomato+ AGM cells.  
(A) Representative FACS plots of cKit+Tomato- and Tomato+ E10 and E11 AGM sorts. Gates 
were based on the unstained sample, cKit staining and Tomato endogenous expression. E10 
AGM cells were sorted only based on Tomato expression (B) Post-sort purity of cKit+Tomato- 
and Tomato+ cells shows no or very little contamination in either sorted population. Numbers 
in the gates correspond to the percentage of cells inside the gate. 
 
At E10, very few colonies were found in the Tomato+ fraction compared to the 
Tomato- fraction. At E11, this number increased in the Tomato+ fraction, 
suggesting that some AGM HSPCs derive from PDGFRβ precursors (Figure 
47). Tomato- and Tomato+ E11 AGM cell transplantations were also 
performed, but no reconstitution was detected in either fraction, suggesting 
that something did not work in the experimental procedure (data not shown).  
 
 
Figure 47. PDGFRβ-Cre;TdTomato+ cells are haematopoietic.  
CFU-C numbers of sorted Tomato- and Tomato+ from PDGFRβ-Cre;TdTomato E10 (33-34sp; 
n=6) and E11 (44-45sp; n=4) AGMs. 
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To understand whether PDGFRβ-Cre;TdTomato-derived HSPCs persisted at 
later stages, haematopoietic progenitor assays were performed on Tomato-
and Tomato+ sorted E14 FL and adult BM cells (Figure 48A, C). Post-sort 
purity was relatively high, with less than 6% contamination of Tomato- cells 
into the Tomato+ E14 FL fraction (Figure 48B), and less than 4% in the 
Tomato+ BM fraction (Figure 48D).  
 
 
Figure 48. Gating strategy and post-sort purity of Tomato- and Tomato+ E14 FL and 
adult BM cells.  
(A) Representative FACS plot of Tomato- and Tomato+ E14 FL cell sorts. An unstained WT 
E14 FL control was used to set the gates for tomato expression. (B) Post-sort purity of E14 FL 
Tomato- and Tomato+ cells. (C) Representative FACS plot of Tomato- and Tomato+ adult BM 
cell sorts. An unstained WT BM control was used to set the gates for tomato expression. (D) 
Post-sort purity of BM Tomato- and Tomato+ cells.  
 
HSPCs were found in both Tomato- and Tomato+ fractions of the E14 FL and 
adult BM (Figure 49). Since the same number of cells was seeded in 
methylcellulose from Tomato- and Tomato+ cells and the percentage of 
Tomato+ cells in each population was different, higher frequencies in HSPCs 
were observed in the Tomato+ E14 FL CFU-Cs and similar frequencies were 
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found in the Tomato+ BM CFU-Cs (not shown). However, this is not 
representative of the total number of HSPCs in each fraction. Therefore, CFU-
C numbers obtained were re-calculated per organ, taking into account the 
percentage of Tomato+ and Tomato- cells and the absolute number of CFU-C 
is shown in Figure 49.  
 
Figure 49. E14 FL and adult BM Tomato+ and Tomato- populations contain HSPCs.  
CFU-C absolute number of sorted Tomato- and Tomato+ from PDGFRβ-Cre;TdTomato (A) 
E14 FL (n=5) and (B) adult BM (n=4). Error bars: SD; **: p<0.01. An unpaired t-test was used 
for the E14 FL data, and an unpaired t-test with Welch’s correction was used for the adult BM 
data.  
 
Flow cytometry analyses were next performed on PDGFRβ-Cre;TdTomato 
E14 FL and adult BM cells to understand whether LSKs (immature progenitors 
and HSCs) were present in both fractions, and at what proportion (Figure 50). 
LSK cells are by definition negative for all haematopoietic lineage markers 
(Lin-: CD4, CD5, CD8a, CD11b, CD45R, Gr-1 and Ter119), and positive for 
cKit and Sca1 [200].  
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Figure 50. LSK gating strategy for PDGFRβ-Cre;TdTomato BM cells.  
Gating strategy for LSK (Lin- Sca1+ cKit+) cells from single live cells. From the LSK population, 
percentages of Tomato- and Tomato+ cells was assessed. A WT BM control was used to set 
the gates separating Tomato- and Tomato+ cells. 
 
Within all LSK cells detected in the E14 FL and adult BM, around 1/10 FL cells 




Figure 51. Tomato- and Tomato+ LSKs are found in both E14 FL and adult BM.  
Percentages of Tomato- and Tomato+ LSK cells detected in the E14 FL (n=5) and adult BM 
(n=3) determined by flow cytometry analysis. Error bars: SD; **: p<0.01; ****: p<0.0001. An 
unpaired t-test was used in both analyses. 
 
To determine whether both Tomato+ and Tomato- fractions contain bona fide 
HSCs, transplantations with Tomato+ and Tomato- sorted cells from PDGFRβ-
Cre;tdTomato E14 FL and adult BM were performed into sub-lethally irradiated 
recipients. After 4 months, 2/4 mice injected with Tomato- and 3/3 mice 
injected with Tomato+ E14 FL cells were successfully reconstituted (Figure 
52A, left graph). Adult BM Tomato- cells reconstituted 4/5 recipients, while 2/5 
mice were reconstituted by Tomato+ (Figure 52B, left graph). Secondary 
transplantations show that HSCs derived from both fractions were able to self-
renew. Together, these data demonstrate that some HSCs derive from 
PDGFRβ-Cre precursors and persist into adulthood. 
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Figure 52. Tomato- and Tomato+ E14FL and adult BM cells contain long-term, self-
renewing HSCs.  
Analysis of long-term reconstitution potential of Tomato- and Tomato+ cells from (A) E14 FL 
(n=4 injected with Tomato-, and n=3 injected with Tomato+ cells) and (B) adult BM (n=5) into 
sub-lethally irradiated recipients 4 months after primary (1o) transplantations  and 1 month 
after secondary (2o) transplantations. BM of mice reconstituted in primary transplantations 
were injected into 2 mice in secondary transplantations. Each data point represents one 
mouse. Mice are reconstituted when >4%  donor cells (dashed line) are found in the host 
peripheral blood. Numbers of reconstituted mice/number of transplanted mice are given in 
each group. 
 
To confirm the data obtained with PDGFRβ-Cre;TdTomato mice, a second 
model was tested. PDGFRβ-Cre;mTmG mice were used by crossing 
PDGFRβ-Cre with R26-mTmG mice (Figure 53). PDGFRβ-Cre mice [160], 
have a sequence encoding the Cre recombinase under PDGFRβ promoter. 
R26-mTmG mice contain a sequence encoding TdTomato and a stop cassette 
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flanked by two loxp sites, followed by a sequence encoding Gfp, both under 
the Rosa26 promoter (Figure 53A) [163]. Upon PDGFRβ expression, Cre 
recombinase is expressed and excises the sequence containing TdTomato 
and the stop cassette, activating GFP expression. GFP+ cells are mainly found 
in the head of PDGFRβ-Cre;mTmG E11 embryos, as well as in the trunk, 
namely in the AGM and neural tube regions (Figure 53B). 
 
Figure 53. PDGFRβ-Cre;mTmG mouse model.  
(A) Schematic representation of PDGFRβ-Cre;mTmG mechanism. (B) PDGFRβ-Cre;mTmG 
E11 embryos, showing Cre+ cells by GFP expression and Cre- cells by TdTomato expression. 
Scale bar: 1mm. 
 
GFP+ and GFP- cells were sorted from E11 AGM and E14 FLs from PDGFRβ-
Cre;mTmG embryos (Figure 54A). Unfortunately, AGM cells (both GFP+ and 
GFP-) failed to generate colonies in methylcellulose, suggesting an underlying 
technical problem, and rendering the experiment unusable (not shown). E14 
FL CFU-Cs were successful, and the post-sort purity for both populations was 
high (Figure 54B,C). Although the frequency of colonies was higher in the GFP 
fraction (not shown), results were re-calculated pre organ, taking into account 
the percentage of sorted cells for each fraction. 
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Both fractions contained HSPCs, and more colonies were found on the GFP- 
fraction compared to GFP+ fraction (Figure 54). Interestingly, the numbers of 
colonies obtained in the GFP+ fraction was much higher than the ones 
obtained using cells sorted from PDGFRβ-Cre;tdTomato (Figure 49). This 
difference is likely due to the larger stringency used to sort Tomato+ cells 
(excluding a Tomato intermediate population), compared to the gate used to 
sort GFP+ cells.  
 
Figure 54. E14 FL GFP+ and GFP- populations contain HSPCs.  
(A) Representative FACS plot of GFP- and GFP+ E14 FL cell sorts. An unstained WT E14 FL 
control was used to set the gates for tomato expression. (B) Post-sort purity of E14 FL Tomato- 
and Tomato+ cells. (C) CFU-C numbers of sorted GFP- and GFP+ from PDGFRβ-Cre;mTmG 
E14 FL (n=5). Error bars: SD; **: p<0.01. A Mann Whitney test was used. 
 
To better understand which cells derive from PDGFRβ progenitors, 
immunohistochemistry was performed on PDGFRβ-Cre;mTmG E11 AGM 
cryosections. As expected, PDGFRβ-Cre (GFP+) was co-expressed by NG2+ 
cells surrounding the DA (Figure 55, upper panel). Several CD31+ cells were 
also found to express GFP (Figure 55, bottom panel), showing that some ECs 




Figure 55. PDGFRβ-Cre expression is detected in PCs and ECs around the E11 DA.  
Immunohistochemistry of PDGFRβ-Cre;mTmG E11 sections stained in red with NG2 (upper 
panel) and CD31 (bottom panel), and PDGFRβ-Cre is expressed by GFP (green). Scale bars: 
upper panel: 50µm; bottom panel: 10µm. 
 
4.4 Discussion 
The main objective of this chapter was to determine whether PDGFRβ 
signalling is required for HSC generation in the AGM.  
4.4.1 PDGFRβ is required for HSPC generation in the AGM  
In Chapter 3, we described PDGFRβ+ cells surrounding the endothelium 
between E9 and E11, during the time of HSC specification and generation, that 
expressed high levels of HSC-niche genes required for HSC maintenance in 
the adult BM. We therefore sought to determine whether PDGFRβ is required 
for HSC generation and/or maintenance in the midgestation AGM. 
Using a constitutive PDGFRβ KO mouse model [157], we assessed HSPC 
numbers in the AGM slightly before HSC generation (E10) and slightly after 
HSC generation has started in this region (E11). No differences were found in 
the number of HSPC at E10, but a significant decrease was detected at E11 
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between PDGFRβ WT, HET and KO embryos (Figure 30). These data suggest 
that PDGFRβ deletion affects AGM haematopoiesis after the onset of HSC 
generation in the AGM (E10.5). However, the AGM region not only harbours 
AGM-derived HSPCs, but also circulating HSPCs from other organs. 
Therefore, the differences detected by CFU-C could be due to defects in HSPC 
production before HSC generation. Importantly, we found that PDGFRβ KO 
AGMs were unable to reconstitute primary sub-lethally irradiated recipients, 
suggesting an underlying defect in HSC generation in the absence of 
PDGFRβ. 
Since PDGFRβ expression was detected in the head, PL, YS and FL from E8 
to E11 (Figure 31), we performed haematopoietic progenitor assays in these 
organs at E10 and E11 to determine whether any similar defects to the AGM 
could be found at these stages. No significant differences were found in any of 
the organs analysed, suggesting that PDGFRβ deletion does not affect 
haematopoiesis in these organs at E10 and E11. This does not exclude the 
possibility PDGFRβ plays a role in primitive haematopoiesis at earlier time-
points, and therefore, additional haematopoietic progenitor assays need to be 
conducted at E8 and E9, to determine whether HSPC production in other 
organs is altered before the onset of AGM haematopoiesis.  
We next looked at whether HSCs were affected in the AGM of PDGFRβ KO 
embryos. Primary transplantations of E11 PDGFRβ KO AGMs led to no 
reconstitution of irradiated recipients in primary transplantations, suggesting 
that the deletion of PDGFRβ affects the generation or maintenance of AGM 
HSCs. Overall reconstitution both in WT and HET mice was low, most likely 
because embryos harvested for injections were under 46sp, and optimal 
reconstitution at E11 occurs with embryos closer to E12. Interestingly, 
transplantations of PDGFRβ KO and PDGF-B KO E14 FLs were shown to 
reconstitute irradiated recipients [201], suggesting that HSCs are present in 
these embryos, although the cellularity of mutant FLs was decreased. This 
could be explained by the generation of HSCs in other haematopoietic organs 
that compensate for the defects HSC generation in the AGM. It would therefore 
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be interesting to perform YS and PL transplantations at E11 to see whether 
they contain HSCs, which would prove their generation outside the AGM.  
4.4.2 PDGFRβ deletion affects the phenotype of PCs but not 
their recruitment to the DA 
Since PDGF-B/PDGFRβ signalling is required for PC/vSMC recruitment and 
blood vessel stabilisation, we hypothesised that the reduction of the number of 
AGM HSPCs could be due to defects in DA integrity and leakage of HSPCs. 
Immunohistochemistry and 3D whole mount immunostaining data at E10 and 
E11 (Figure 35 andFigure 38) suggest that the integrity of the DA is not 
compromised by PDGFRβ deletion, as seen by a continuous CD31 expression 
and no leakage of cKit+ cells to the surrounding mesenchyme. Interestingly, 
although no expression of PDGFRβ was detected in KO embryos, NG2+ 
αSMA+ perivascular cells were still present, suggesting that pericyte/vSMC 
recruitment around the aorta is independent of PDGF-B/PDGFRβ signalling. 
The presence of these cells in the absence of PDGFRβ signalling also 
suggests that rather than being recruited, their differentiation into PC/vSMCs 
is induced instead, most likely via TGFβ signalling [197], and possibly through 
Notch signalling as well [197]. Although NG2+ αSMA+ perivascular cells are 
detected around the aorta of mutant embryos, we found a significant decrease 
in NG2 expression at E10.5 and an increase in the percentage of αSMA+ cells 
and αSMA intensity around the DA (Figure 35 andFigure 37). These results 
were further confirmed by flow cytometry. Such changes in NG2 and αSMA 
expression have been reported at later time-points in WT dorsal aorta. As the 
blood vessel matures, developing vSMCs lose NG2 expression and αSMA 
expression increases [179]. Moreover, it was recently shown that inhibiting 
VEGFR/PDGFR with axitinib led to the induction of αSMA expression and a 
pro-fibrotic phenotype in human placental pericytes [202]. These data suggest 
that PDGFRβ deletion leads to a premature differentiation of PCs into a more 
mature vSMC phenotype, marked by an increase in αSMA expression and 
αSMA+ cells around the aorta, coupled with a decrease in NG2 expression. 
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4.4.3 PDGFRβ deletion affects IAHC size 
Another interesting observation in E10.5 PDGFRβ KO DAs was that cKit+ 
clusters are larger than WT clusters. Recently, large sized clusters were found 
in the E10.5 DA of mice constitutively lacking the Notch ligand Dll4 [203]. 
Although the perivascular cell populations around the AGM do not express any 
notch ligand (see Dll1, 3, 4 and Jag2 in appendix table 3) with the exception of 
Jagged1, PDGFRβ+ cells could play a role in the regulation of Notch signalling. 
It would be interesting to see whether the Notch signalling pathway is altered 
in the AGMs of PDGFRβ KO embryos. Another similar phenotype has been 
reported in Drosophila when the PDGF/VEGF receptor is deleted, and 
haemocytes undergo apoptosis and are phagocytosed by the remaining blood 
cells [152]. It would be interesting to examine the expression of apoptotic 
markers in the murine PDGFRB KO aorta to determine whether IAHCs contain 
more apoptotic cells.  
4.4.4 Collagen IV deposition is not affected by the absence of 
PDGFRβ 
No differences were found in collagen IV nor CD146 expression around the 
dorsal aorta of PDGFRβ KO E11 embryos by immunohistochemistry. 
Basement membrane assembly was shown to rely on the interaction between 
pericytes and endothelial cells, and therefore, on pericyte recruitment to the 
blood vessel wall [185,186,204]. Although the blockage of PDGF-BB in vitro 
was shown to impair pericyte recruitment to EC tubes and decrease collagen 
IV deposition [186], collagen IV expression around the DA was normal. This is 
not surprising, given that NG2+ αSMA+ cells are still present around the aorta 
of mutant embryos. However, the basement membrane is complex, and many 
other proteins are involved in the basement membrane synthesis, such as 
laminins and integrins [204], and PDGFs were shown to play a role in the 
production of extracellular matrix components [144,145]. It would therefore be 
interesting to determine whether other components of the basement 
membrane are affected in these embryos.   
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4.4.5 E10 AGM haemogenic endothelial cells are affected by 
PDGFRβ deletion 
As HSCs were not detected in the AGM of PDGFRβ KO embryos, we sought 
to determine whether haemogenic endothelial cells were affected by PDGFRβ 
deletion. For this purpose, PDGFRβ mutant mice were crossed with Runx1-
IRES-GFP mice, and F2 embryos were analysed by flow cytometry. A 
significant decrease in the percentage of HECs was detected at E10. This 
decrease could still be observed at E11, but was not statistically significant. 
Runx1 expression by ECs was shown to be essential for endothelial to 
haematopoietic transition, but not afterwards [79]. These data suggest that 
PDGFRβ is important either for the specification of HECs and/or as HEC 
precursors. In the chick embryo, it was shown that the presence of a 
splanchnopleura-derived sub-aortic mesenchyme (where PDGFRβ is 
expressed in the mouse) was required for the induction of Runx1 expression 
by endothelial cells, and subsequent HSPC formation [97]. PDGFRβ signalling 
could therefore be required to signal endothelial cells to express Runx1 and 
initiate aortic haematopoiesis. In zebrafish for instance, PDGFR signalling 
(mainly PDGFRα but also PDGFRβ) was shown to be necessary for the 
migration of neural crest cells to the ventral aspect of the DA. Morpholino knock 
down of pdgfra and pdgfrb halted this migration, which in turn led to a reduction 
of Runx1-expressing cells [148]. Understanding whether this niche effect is 
conserved in mice would bring additional cues to understanding this reduction 
in HECs.  
As Runx1 is also expressed in mesenchymal and haematopoietic cells [47], 
Runx1 expression by these cells was also assessed by flow cytometry. The 
percentages of Runx1+ HSPCs were similar in WT, HET and KO at both E10 
and E11 suggesting that PDGFRβ deletion only affects HECs and not HSPCs 
(Figure 42). The percentage of Runx1+ stromal cells was unchanged between 
WT, HET and KO E10 AGMs, but a marked decrease was observed in the 
stroma at E11 (Figure 43). The role of stromal cell expressing Runx1 is 
however unknown. Our unpublished observations show that the deletion of 
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Runx1 in stromal cells impairs AGM haematopoiesis (Gonzalez et al, In 
Preparation).   
4.4.6 Midgestation PDGFRβ+ cells are not haematopoietic, but 
a subset of HSPCs derives from PDGFRβ-Cre precursors 
As AGM HSPCs were affected by the deletion of PDGFRβ, we sought to 
determine whether midgestation HSPCs express this marker. Haematopoietic 
progenitor assays with AGM PDGFRβ- and PDGFRβ+ sorted cells showed no 
colony formation in the PDGFRβ+ fraction (Figure 45). We can therefore 
conclude that PDGFRβ deletion does not affect HSPCs directly, as they do not 
express PDGFRβ.  
Another possible explanation for the effect of PDGFRβ deletion in the AGM is 
that PDGFRβ+ cells are precursors of AGM HSPCs. To test this possibility, 
PDGFRβ-Cre mice were crossed with TdTomato mice, AGM cells were sorted 
based on Tomato expression and seeded in methylcellulose. At E10, a small 
fraction of Tomato+ cells were able to form colonies, and this number 
increased at E11, suggesting that PDGFRβ-Cre marks some HSPC (Figure 
47). As their numbers increase between E10 and E11, the period in which 
AGM HSCs are generated, it is plausible to postulate that these cells could be 
generated by the AGM. To confirm this possibility, CFU-Cs will need to be 
performed with Tomato+ and Tomato- cells sorted from other haematopoietic 
organs before the onset of AGM haematopoiesis. Interestingly, the deletion of 
PDGFRβ led to a decrease in nearly half of haematopoietic progenitors in the 
AGM (Figure 32), which could be explained by the finding that about 1/3 of 
AGM HSPCs derive from PDGFRβ-Cre precursors (Figure 47). These data do 
not exclude the possibility that PDGFRβ-Cre-derived HSPCs are produced in 
other haematopoietic organs. Tracing experiments using the same PDGFRβ-
Cre mouse line as the one used in this study showed that although PDGFRβ-
Cre is expressed in YS ECs, it does not target cKit+ E9 and E10 YS-derived 
EMPs, suggesting that PDGFRβ precursors do not contribute to YS 
haematopoietic cells [205]. Ongoing experiments in the lab aim to confirm 
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these data and address this question in other haematopoietic organs before 
HSC generation in the AGM. 
To understand whether PDGFRβ-Cre-derived HSPCs persist during 
development and in the adult, CFU-Cs were performed with sorted Tomato 
cells from the E14 FL and adult BM. Tomato+-derived colonies were detected 
in both tissues, although in lower numbers than in the Tomato- fraction (Figure 
49), suggesting that PDGFRβ-Cre-derived HSCs persist into adulthood. It 
would also be possible that PDGFRβ-Cre-derived HSCs are generated de 
novo after AGM haematopoiesis. To rule out this possibility, it would be 
important to trace PDGFRβ-Cre-derived cells after AGM haematopoiesis, 
using for example PDGFRβ-P2A-CreERT2;mTmG [206] embryos injected with 
tamoxifen after E12 and determine whether GFP+ HSCs are present in both, 
the E14 FL and in the adult BM.  
LSK analysis was also performed in these organs to determine the percentage 
of immature HSPCs in each fraction. Unfortunately, LSK-SLAM analysis could 
not be performed due to a spectral overlap of the CD48 (Slamf2) PE antibody 
with TdTomato to see whether any of the fractions was more enriched in 
specific types of HSPCs. On average, 1/10th of FL LSKs were found in the 
tomato+ fraction, and this number increased to 1/4th in the adult BM (Figure 
51), suggesting that PDGFRβ-Cre cells give rise to immature haematopoietic 
progenitors. To test whether both fractions contained bona fide HSCs, sorted 
Tomato+ and Tomato- cells from E14 FL and adult BM were injected into 
irradiated recipients. Both fractions were found to reconstitute primary 
recipients after 4 months and secondary recipients after 1 month, suggesting 
that both fractions contain long-term reconstituting HSCs (LTR-HSCs).  
4.4.7 A subset of aortic ECs derives from PDGFRβ-Cre 
precursors 
The existence of PDGFRβ-Cre-derived HSCs suggests that some HECs 
derive from PDGFRβ-Cre precursors. We looked at CD31 expression in 
PDGFRβ-Cre;mTmG E11 AGM sections and found that most, if not all CD31+ 
cells at this stage also express GFP (Figure 55). PDGFRβ-Cre expression in 
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ECs of the dorsal aorta has already been reported at E13.5 [205]. These 
results are not surprising, as both ECs and SMCs in the murine dorsal aorta 
were shown to derive from common precursors from the lateral plate 
mesoderm before HSC generation [139,207]. Although in the chick embryo 
aortic ECs were shown to be replaced by somite-derived ECs following HSC 
generation [137], in the mouse this does not seem to be the case, and ECs 
from the lateral plate mesoderm are maintained in the DA after E11.5 [139]. 
This might explain why GFP+ ECs are still present in the DA at E11.5. To 
confirm these data, analysis of PDGFRβ-P2A-CreERT2 E11 embryos born 
from females injected with tamoxifen at either E7, E8 or E9 is underway. 
Whether HECs derive from PDGFRβ precursors is still under investigation. We 
crossed PDGFRβ-Cre;tdTomato with Runx1-GFP mice to determine the 
percentage of tdTomato+ HECs. Unfortunately, an unknown biological effect 
occurs with this crossing and the presence of Runx1-GFP induces tdTomato 
expression in almost 100% of the cells (not shown). Flow cytometry analysis 
of PDGFRβ-Cre;tdTomato using CD41 as HEC marker, together with 
immunohistochemistry with Runx1 antibody staining will be performed instead, 
to determine PDGFRβ contribution to the haemogenic endothelium. If all AGM 
HECs derive from PDGFRβ-Cre precursors, it will confirm that there are other 
sites for the generation of HSCs that persist into adulthood. 
4.4.8 Conclusions and future work 
In this chapter we have shown that PDGFRβ is required for HSC generation in 
the AGM. Deletion of PDGFRβ led to a reduction of HECs and a change in the 
phenotype of PCs surrounding the DA. Single cell RNA sequencing analysis 
is currently underway in E11 PDGFRβ WT and KO embryos, to determine if 
there are any signalling pathways affected by PDGFRβ deletion that could 
impair HSC generation and/or maintenance in the AGM. 
We have also shown that a subset of HSCs that persist into adulthood derive 
from PDGFRβ-Cre precursors, while others do not, suggesting a dual origin 
for HSCs.  Ongoing experiments investigating the presence of PDGFRB-
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derived HPSCs in other organs will allow us to determine whether PDGFRβ is 
only required for HSC generation in the AGM or could also play a role in other 
haematopoietic organs. If PDGFRβ-Cre only marks AGM haematopoietic 
cells, this study will prove that adult-type HSCs can also be produced outside 
the AGM. 
It would also be interesting in the future to analyse the BM of PDGFRβ-
Cre;TdTomato mice and determine whether PDGFRβ-Cre-derived HSCs and 
HSCs from another origin are genetically distinct. For instance, previous work 
showed that a subset of FL and BM HSCs is BMP-activated and another 
subset is not [208]. It would therefore be interesting to investigate whether 
PDGFRβ-derived HSCs are BMP-dependent or BMP-independent.   
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Chapter 5 PDGF-Bret mutation in 
haematopoiesis 
5.1 Introduction 
PDGF-B signalling via PDGFR-β is critically involved in the recruitment of 
pericytes and vascular smooth muscle cells to blood vessels [182,209]. PDGF-
B is expressed by endothelial cells, and once released, binds to the 
extracellular matrix surrounding the endothelium, creating a gradient required 
for the proper recruitment and investment of pericytes to blood vessel walls 
[158]. Interestingly, overexpression of PDGF-B in zebrafish was shown to lead 
to an increase in AGM HSPC production [149]. Similarly to PDGFRβ KO 
embryos [157], PDGF-B KO embryos also die perinatally [210]. These 
embryos have abnormal kidney glomeruli due to a defect in mesangial cell 
development, heart and blood vessel dilation, anaemia, thrombocytopenia and 
are thought to die of haemorrhages [210].  
As PDGF-B/PDGFRβ signalling is required for important developmental 
processes and we found that PDGFRβ+ cells are precursors to a subset of 
HSCs in Chapter 4, we sought to determine whether proper PDGF-B/PDGFRβ 
signalling between endothelial cells and pericytes is required for embryonic 
and adult haematopoiesis. As both PDGFRβ and PDGF-B KO embryos die 
perinatally [157,209], we used a mouse model called PDGF-Bret that survives 
into adulthood, with a milder phenotype than the ones of PDGFRβ and PDGF-
B mice [158]. In this model, PDGF-B has a mutation in its retention domain 
and cannot bind to the extracellular matrix surrounding ECs. Therefore, PDGF-
B does not accumulate and create a gradient necessary for proper pericyte 
investment to the blood vessel wall [158]. As a result, PDGF-Bret KO mice have 
defective PDGF-B/PDGFRβ signalling between pericytes and endothelial 
cells, and pericytes are deficiently recruited to the blood vessel wall. As a 
consequence, pericytes and vSMCs are found around blood vessels, but in 
lower numbers, and their processes detach from the endothelium. PDGF-Bret 
KO mice have defects in mesangial cells in the kidneys which leads to 
glomerulosclerosis, proteinuria, and severe deterioration of the retina [158]. As 
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PDGF-Bret KO mice survive into adulthood, the role of PDGF-B/PDGFRβ 
signalling can also be studied in adult haematopoiesis. 
5.2 Hypothesis and aims 
5.2.1 Hypothesis 
PDGF-B retention motif deletion affects haematopoiesis either due to defects 
in PDGF-B/PDGFRβ signalling or pericyte/vSMC recruitment to the 
midgestation dorsal aorta. 
5.2.2 Aims 
- Determine whether PDGF-B retention motif deletion affects AGM 
HSPCs. 
- Determine whether PDGF-B retention motif deletion affects HSPCs in 
other haematopoietic organs. 
- Determine whether PDGF-B retention motif deletion affects the 
recruitment of pericytes to the dorsal aorta or the interaction between 
PCs and ECs. 
- Understand whether perivascular cell populations surrounding the 
dorsal aorta are affected by a deficient PDGF-B/PDGFRβ signalling in 
the dorsal aorta. 
- Determine whether adult haematopoiesis is affected in PDGF-Bret KO 
mice. 
5.3 Results 
5.3.1 PDGF-Bret mutation during embryonic development 
5.3.1.1 AGM HSPCs 
To understand whether a deletion of PDGF-B retention motif affects AGM 
haematopoiesis, haematopoietic progenitor assays were performed with E11 
PDGF-Bret mutant AGMs. Due to large deviations in the number of colonies 
obtained from early E11 (40-43sp) embryos compared to late E11 (44-46sp) 
embryos, results were plotted separately. No significant differences were 
found in PDGF-Bret mutants at early E11 (Figure 56, Table 30). In late E11 
mutants, differences were found between HET and KO embryos, with a 
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significant decrease in the number of KO BFU-E, CFU-G, CFU-GEMM (Table 
30) and in the total number of CFU-C compared to heterozygous mice (Figure 
56, Table 30).  
 
Figure 56. Total HSPC numbers decrease between PDGF-Bret HET and KO late E11 
embryos.  
Number of colonies (CFU-C) per PDGF-Bret WT, HET and KO early E11 (40-43sp) and late 
E11 (44-46sp) AGMs. **: p<0.01. 
 
Table 30. Summary of CFU-C data for PDGF-Bret WT, HET and KO E11 AGMs. 
Haematopoietic progenitor assays were performed for PDGF-Bret WT, HET and KO early E11 
(40-43sp) and late E11 (44-46sp) AGMs. The number of embryos, CFU-C per tissue (mean ± 
SD), fold changes in CFU-C numbers between WT, HET and KO mice, the statistical tests 
used, p values and multiple comparison tests are shown here. Significant differences are 





5.3.1.2 HSPCs in other haematopoietic organs 
To determine whether HSPCs are affected by PDGF-Bret deletion in other 
haematopoietic organs at the time of HSC generation, haematopoietic 
progenitor assays were performed in E11 embryos (40-43sp) (Figure 57, Table 
31). No significant differences were found in the total number of colonies in 
PDGF-Bret mutant E11 head, PL and FL, with the exception of the YS, where 
differences were detected, however post-hoc test was not sensitive enough to 
find where the difference lies (Figure 57, Table 31). KO BFU-Es in both the FL 
and the PL were also significantly reduced compared to WT BFU-Es, and there 
was a significant increase between HET and KO CFU-GEMM in the head 
(Table 31). No other differences were found in HSPCs of E11 haematopoietic 





Figure 57. HSPCs in the head, foetal liver, placenta and yolk sac are not affected in 
E11 PDGF-Bret mutants.  
CFU-C numbers per PDGF-Bret WT, HET and KO E11 (40-43sp) head, FL, PL and YS.  
 
Table 31. Summary of CFU-C data for PDGF-Bret WT, HET and KO E11 haematopoietic 
organs.  
Haematopoietic progenitor assays were performed for PDGF-Bret WT, HET and KO early E11 
(40-43sp) head, FL, PL and YS. The number of embryos, CFU-C per tissue (mean ± SD), fold 
changes in CFU-C numbers between WT, HET and KO mice, the statistical tests used, p 
values and multiple comparison tests are shown here. Significant differences are indicated 







5.3.1.3 HSCs from PDGF-Bret KO embryos fail to reconstitute 
secondary recipients 
Although few differences were detected in haematopoietic progenitor assays, 
HSCs could still be affected in PDGF-Bret KO embryos. E11 AGMs were 
therefore injected into sub-lethally irradiated recipients, and the percentage of 
donor chimerism assessed in the peripheral blood of transplanted mice after 4 
months. Positive reconstitution was detected in 4/21 mice injected with PDGF-
Bret WT AGM cells, 8/28 with HET AGM cells and 4/19 with KO AGM cells 
(Figure 59A). This suggests that the deletion of PDGF-B retention motif does 
not affect long-term reconstitution potential. To test whether these cells self-
renew, secondary transplantations were performed. The whole BM of 
positively reconstituted recipients was injected into two sub-lethally irradiated 
recipients (Figure 58), and peripheral blood was analysed after 1 and 4 months 
following transplantation (Figure 59B). Whereas WT and HET donor HSCs 
were found to self-renew, KO donor cells did not. No difference in lineage 
reconstitution was detected between positively reconstituted mutants in both 
primary and secondary transplantations (not shown). 
 
Figure 58. Secondary transplantations.  
Schematic representation of secondary transplantation procedure. Whole BM cells from a 
successfully reconstituted recipient were injected into two sub-lethally irradiated Ly5.1/.2 




Figure 59. Self-renewal of PDGF-Bret KO E11 HSCs is impaired.  
(A) Percentages of donor chimerism is shown after 4 months following primary 
transplantations, and (B) 4 months following secondary transplantations into sub-lethally 
irradiated recipients. BM of mice reconstituted in primary transplantations were injected into 2 
mice in secondary transplantations. Each dot represents one transplanted mouse. Mice are 
reconstituted when >4% donor cells are found in the host peripheral blood (dotted line). 
Number of reconstituted mice/number of transplanted mice are given in each group. A two 
proportion Z-test was used to test for significance. 
 
5.3.1.4 The dorsal aorta is properly formed in PDGF-Bret KO 
midgestation embryos 
To understand whether PDGF-B retention is important for the formation and 
integrity of the dorsal aorta, 3D-whole mount immunostainings were performed 
on E10.5 PDGF-Bret mutant embryos (Figure 60). cKit expression was 
detected in haematopoietic clusters of both PDGF-Bret WT and KO embryos, 
as expected, with no visible differences in the size of clusters between WT and 
KO. No differences were observed in DA morphology, and its integrity was not 
affected (Figure 60). A slight increase in αSMA expression was detected 




Figure 60. DA is properly formed in PDGF-Bret KO E10.5 embryos.  
Confocal images of whole-mount immunostainings of PDGF-Bret WT and KO E10.5 DAs 
stained with cKit (cyan), αSMA (yellow) and CD31 (magenta). Scale bars: 100µm. 
 
To understand whether the distribution of the different perivascular cell 
populations surrounding the DA was altered by the lack of PDGF-B retention 
motif, immunohistochemistry analysis was performed in PDGF-Bret WT and KO 
embryos. E11 cryosections were first stained with PDGFRβ and CD31. No 
differences in PDGFRβ expression and distribution were detected in the KO 
embryos (Figure 61). CD31 expression appeared normal, confirming the whole 
mount immunostaining data (Figure 60 andFigure 61).  
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Figure 61. PDGB-Bret KO does not affect PDGFRβ expression around the DA and CVs.  
Immunohistochemistry on PDGF-Bret WT and KO E11 cryosections stained with PDGFRβ 
(green) and CD31 (red). Nuclei were counterstained with DAPI. Scale bars: 100µm. 
 
Sections were next stained with NG2 and CD31. NG2 expression appeared to 
be normal both around the DA as well as around the notochord in PDGF-Bret 
KO E11 embryos. In the WT sections, NG2 expression was absent near and 
around the ISVs (Figure 62). This is in line with the data obtained by 3D-whole 
mount immunostaining in Chapter 4 (Chapter 4, Figure 35B), suggesting that 
only the dorsal aorta and umbilical and vitelline arteries are surrounded by 




Figure 62. PDGB-Bret KO does not affect NG2 expression around the DA and NC.  
Immunohistochemistry on PDGF-Bret WT and KO E11 cryosections stained with NG2 (green) 
and CD31 (red). Nuclei were counterstained with DAPI. Scale bars: 100µm. 
 
Double staining with NG2 and PDGFRβ was next performed. PCs and sub-
PCs were detected in both PDGF-Bret WT and KO, suggesting that deletion in 




Figure 63. NG2+ PDGFRβ+ PCs are unaffected in PDGF-Bret KO E11 embryos.  
Immunohistochemistry on PDGF-Bret WT and KO E11 cryosections stained with PDGFRβ 
(green) and NG2 (red). Nuclei were counterstained with DAPI. Scale bars: 100µm. 
 
Staining with αSMA was also performed, and no difference was detected in 
the distribution of αSMA+ cells in the KO embryos. However, αSMA expression 
in PDGF-Bret KO appeared slightly higher than in the WT (Figure 64), in line 





Figure 64. αSMA expression is slightly increased around PDGF-Bret KO E11 DA. 
Immunohistochemistry on PDGF-Bret WT and KO E11 cryosections stained with αSMA 
(green) and CD31 (red). Nuclei were counterstained with DAPI. Scale bars: 100µm. 
 
CD146 expression was also assessed, and no differences were found in 
PDGF-Bret KO embryos compared to WT (Figure 65).  
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Figure 65. CD146 expression was not altered in PDGF-Bret KO E11 embryos.  
Immunohistochemistry on PDGF-Bret WT and KO E11 cryosections stained with CD146 
(green) and CD31 (red). Nuclei were counterstained with DAPI. Scale bars: 100µm. 
 
Lastly, Collagen IV staining was also performed, and no differences in 
Collagen IV expression were detected between PDGF-Bret WT and KO 
embryos (Figure 66). 
 
 
Figure 66. Collagen IV expression is not affected in PDGF-Bret KO E11 embyros.  
Immunohistochemistry on PDGF-Bret WT and KO E11 cryosections stained with Collagen IV 
(green) and CD31 (red). Nuclei were counterstained with DAPI. Scale bars: 100µm. 
 
5.3.1.5 PDGF-Bret mutation does not affect the cellular composition of 
the midgestation AGM 
To understand whether PDGF-Bret mutation affects the normal composition of 
cells in the AGM, E11 embryos were analysed by flow cytometry. Single live 
AGM cells were analysed for the expression of different markers (Figure 67). 
No differences were found in the percentages of any of the markers analysed 




Figure 67. No differences in percentages of E11 AGM cell populations were found in 
PDGF-Bret mutants.  
Percentage of CD31+, CD45+, cKit+, NG2+, PDGFRβ+ and PDGFRα+ single viable cells in 
PDGF-Bret analysed by flow cytometry. 9 WT, 15 HET and 5 KO embryos were analysed. 
 
The percentages of endothelial cells (CD31+ cKit- CD45-) and HSPCs (CD31+ 
cKit+ NG2- PDGFRβ-) were also assessed (Figure 68). HSPCs were analysed 
based on the absence of the perivascular cell markers PDGFRβ and NG2, 
because we found in the previous chapter that PDGFRβ+ cells are not 
haematopoietic (Chapter 4, Figure 17), nor are NG2+ cells (Gonzalez et al., In 
Preparation). Deletion of PDGF-B retention motif did not affect the 
percentages of ECs not HSPCs (Figure 68).  
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Figure 68. Flow cytometry analysis of ECs and HSPCs from E11 PDGF-Bret mutants.  
(A) Gating strategy used to analyse ECs (CD31+ CD45- cKit- single live cells). (B) 
Percentages of ECs in PDGF-Bret WT, HET and KO E11 embryos. (C) Gating strategy used 
to analyse HSPCs (CD31+ cKit+ NG2- PDGFRβ- single live cells). (D) Percentages of HSPCs 
in PDGF-Bret WT, HET and KO embryos. 9 WT, 15 HET and 5 KO embryos were analysed.  
 
Perivascular cell percentages were next assessed to understand whether 
PDGF-Bret mutation affected their numbers. No differences were found in any 





Figure 69. Flow cytometry analysis of the three perivascular cell populations in PDGF-
Bret WT, HET and KO E11 AGMs.  
(A) Gating strategy used to analyse the percentages of the three perivascular cell populations 
described in Chapter 3 by flow cytometry. (B) Percentages of NG2+ PDGFRβ- notochord cells, 
PCs, sub-PCs and stroma in E11 PDGF-Bret mutants. 9 WT, 15 HET and 5 KO embryos were 
analysed.  
 
Because PDGF-B is also a ligand of PDGFRα, a mutation in PDGF-B retention 
motif could potentially lead to an increase in PDGFRα expression in the AGM 
to compensate for the diffusion of PDGF-B. Therefore, PDGFRα expression 
was analysed in HSPCs, ECs and perivascular cells by flow cytometry. No 
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changes were detected in PDGFRα expression in any population analysed. 
We also found that PDGFRα was highly expressed in PCs and sub-PCs (in 
approximately 80% of cells) (Figure 70). These data suggest that there is no 
PDGFRα compensation around the DA due to the PDGF-Bret mutation.  
 
 
Figure 70. PDGFRα expression in PDGF-Bret E11 mutant HSPCs, ECs, and perivascular 
cells.  
Flow cytometry analyses of PDGFRα+ HSPCs, ECs, NG2+ PDGFRβ- notochord cells, PCs, 
sub-PCs and stroma. 9 WT, 15 HET and 5 KO embryos were analysed.  
 
5.3.2 PDGF-Bret adult BM haematopoiesis 
5.3.2.1 Haematopoietic progenitors are not affected by the deletion of 
PDGF-B retention motif. 
To understand whether PDGF-B retention defects affect adult haematopoiesis, 
haematopoietic progenitor assays were performed on BM cells of PDGF-Bret 
WT, Het and KO adult mice. No significant differences in the number of 
progenitors between PDGF-Bret WT, HET and KO were found (Figure 71), 
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suggesting that PDGF-Bret mutation does not affect HSPC homeostasis in the 
adult BM.   
 
Figure 71. Haematopoietic progenitor assays.  
CFU-Cs per 10000 cells of PDGF-Bret adult BM seeded. WT: n=8; HET: n=7; KO: n=3. 
 
5.3.2.2 No significant differences in LSK-SLAM populations in the adult 
BM of PDGF-Bret mutants 
LSK-SLAM analysis was performed on PDGF-Bret mutant BM cells to 
determine whether there are any differences in the most immature 
haematopoietic progenitors and HSCs due to the deletion of PDGF-B retention 
motif (Figure 72). LSK (Lin- Sca1+ cKit+) HSCs [211–213] were selected by 
the absence of lineage surface markers (Lin-) and presence of Sca1 and cKit, 
and further purified into four populations based on the expression of the SLAM 
family markers CD48 and CD150 [212,213] (Figure 72A). Within the LSK 
population, CD48+CD150- (HPC1) and CD48+CD150+ (HPC2) cells are 
restricted progenitors, while CD48-CD150- cells (MPPs) are non-self-renewing 
or transiently reconstituting multipotent progenitors, and CD150+CD48- cells 
are HSCs. No differences were found in PDGF-Bret mutant BMs in any of the 
populations analysed (Figure 72B), suggesting that PDGF-Bret mutation does 
not alter the frequency of immature haematopoietic progenitors and stem cells 
in the BM. 
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Figure 72. LSK-SLAM analysis of PDGF-Bret adult BM.  
(A) Gating strategy for LSK cells from single live cells and the expression of the SLAM family 
markers CD150 (Slamf1) and CD48 (Slamf2) within the LSK population in PDGF-Bret WT, HET 
and KO adult BM. Within LSK HSPCs, HPC1 (CD48+ CD150-) and HPC2 (CD48+ CD150+) 
contain restricted progenitors; MPPs (CD48- CD150-) contain non-self-renewing or transiently 
reconstituting multipotent progenitors. The CD150+ CD48- fraction contains highly purified 
HSCs. (B) Percentages of the different populations of LSK-SLAM obtained by flow cytometry. 
WT: n=4; HET: n=5; KO: n=3.  
 
5.3.2.3 Self-renewing haematopoietic stem cells are present in the BM 
of PDGF-B mutants.  
To understand whether BM HSCs are affected, BM cells from PDGF-Bret WT, 
Het and KO mice were transplanted into sub-lethally irradiated recipients. No 
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significant differences in reconstitution were found after 4 months between 
WT, HET and KO BM cells both in primary (Figure 73) and secondary 
transplantations (Figure 73). In addition, there were no differences in lineage 
reconstitution (lymphoid and myeloid) between mutants (not shown). Together, 
these data suggest that adult HSCs are not affected by the deletion of PDGF-
B retention motif.   
 
Figure 73. PDGF-Bret BM contain self-renewing HSCs.  
Percentages of donor chimerism 4 months after (A) primary transplantations and (B) 
secondary transplantations with PDGF-Bret adult BMs. Each dot represents one transplanted 
mouse. Mice are reconstituted when >4% donor cells are found in the host peripheral blood 
(dotted line). Numbers on the graph represent the number of mice that was reconstituted per 
number of mice injected.  
 
5.4 Discussion 
Since PDGF-B and PDGFRβ KO embryos die perinatally, we sought to 
determine whether defective PDGF-B/PDGFRβ signalling affects murine 
embryonic and adult haematopoiesis with the use of PDGF-Bret mutant mice.  
5.4.1 PDGF-Bret AGM-derived HSCs fail to reconstitute 
secondary recipients 
PDGF-B overexpression in zebrafish was shown to increase the percentage 
of HSPCs in the dorsal aorta [149]. We therefore hypothesised that defects in 
PDGF-B retention around the endothelium would decrease the number of 
HSPCs found in the AGM, due to a defective PDGF-B/PDGFRβ signalling 
between pericytes and endothelial cells.   
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Although no differences were detected between WT and KO AGM HSPCs, we 
sought to determine whether HSCs were affected by PDGF-B mutation. 
PDGF-Bret KO embryos appear to contain HSCs that reconstitute primary 
recipients but fail to reconstitute secondary recipients (Figure 59), suggesting 
that PDGF-Bret KO AGMs fail to generate long-term reconstituting HSCs. Due 
to the low number of reconstituted mice and the low number of mice injected 
in secondary transplantations, these results remain inconclusive. Additional 
secondary transplantations from PDGF-Bret KO reconstituted primary 
recipients should be performed to confirm these results. If these data are 
confirmed, it would support the hypothesis that HSCs generated in other 
haematopoietic organs during development are able to take over FL and adult 
haematopoiesis, as was proposed in Chapter 4. This would further suggest 
that a proper ECs communication with adjacent perivascular cells is required 
to maintain HSCs immature.  
5.4.2 PDGF-Bret KO midgestation embryos exhibit an 
apparently normal dorsal aorta and surrounding 
perivascular cells 
PDGF-B retention to the extracellular matrix was shown to be required for the 
proper investment of pericytes to the blood vessel wall, as it creates a PDGF-
B gradient required for PDGFRβ+ pericytes/vSMCs recruitment [158,159,199]. 
PDGF-Bret KO embryos exhibit a partial detachment of pericytes from the 
endothelium and have a leaky vasculature [158]. Whether this mutation also 
affects large vessels, has not been reported. To address this question, 
immunohistochemistry in both DA whole-mounts and cryosections of mutant 
AGMs was performed. The dorsal aorta of KO embryos was properly formed 
and the perivascular cell coverage appeared unchanged. A slight increase in 
αSMA expression was detected in the PDGF-Bret KO whole-mount (Figure 60), 
but not as striking as the one detected in PDGFRβ KO embryos. This slight 
increase needs to be further confirmed with additional whole-mounts and by 
flow cytometry.  
Immunohistochemistry was performed with different combinations of 
perivascular and endothelial markers, to determine whether PDGF-Bret KO 
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affected perivascular cell distribution around the DA. It is important to note that 
the expression levels of the different markers between WT and KO embryos 
cannot be compared. At the time of the analysis of these data, the 64GB RAM 
computer that was used to analyse and mount the pictures for Chapter 4 was 
broken. As a consequence, these files had to be analysed by a 16GB RAM 
computer that could not open the WT and KO files simultaneously, and 
therefore brightness and contrast could not be equally matched in FIJI/ImageJ. 
Despite the technical difficulties in the analysis, presence of the different 
perivascular cells can be seen, and no differences were detected in the 
distribution of PCs, sub-PCs and stromal cells. In addition, PDGFRβ 
expression was present in both WT and KO embryos, suggesting that PDGF-
Bret mutation does not affect PDGFRβ expression, nor pericyte/vSMC 
recruitment to the dorsal aorta. A new analysis of αSMA, NG2 and PDGFRβ 
levels should be performed again, matching the brightness/contrast changes 
between WT and KO embryos to determine whether expression levels vary 
upon PDGF-B retention motif deletion.  
Recent RNA sequencing analysis on E11 AGM endothelial cells in our lab 
found high expression of pdgfb in these cells (not shown). Antibody staining 
against PDGF-B was therefore tested to determine the pattern of PDGF-B 
expression around the aortic endothelium, but the antibodies did not work on 
frozen and paraffin sections (not shown). We could therefore not validate the 
presence of pdgfb in the dorsal aorta at the protein level. The best visualisation 
of PDGF-B has so far been achieved by in situ hybridisation (ISH) [182]. It 
would be important to perform ISH in the dorsal aorta to assess PDGF-B 
expression. Some studies found that it is only expressed in tip cells during 
angiogenesis [182,209], however, not much data is available on PDGF-B 
expression during vasculogenesis and whether it is normally expressed 
around the dorsal aorta at the time of HSC generation. Indeed, the presence 
of PDGFRβ around the aorta was found already at E9 (see Chapter 4) and is 
expected to be present even earlier. Thus, PDGF-B/PDGFRβ signalling may 
have started at early developmental time points with mRNA expression 
persisting at later stages.  Although PDGF-B role in the recruitment, 
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proliferation and differentiation of pericytes and vSMCs has mainly been 
reported in angiogenic sprouts [182,209], it is believed that it might also play a 
role in aortic and venous PCs/vSMCs [193]. Characterisation of PDGF-B 
expression in the developing DA needs to be performed to conclude whether 
in fact, PDGF-B diffuses in PDGF-B retention motif KO AGMs compared to 
WT, and to what extent PDGF-B/PDGFRβ signalling is affected. It would be 
interesting to perform western blotting analysis on the level of PDGFRβ 
phosphorylation (which marks activated PDGFRβ) in WT and KO AGMs.  
In addition, although no differences in collagen IV expression were detected 
between PDGF-Bret WT and KO embryos, it would be interesting to determine 
whether other extracellular matrix proteins are affected in mutant embryos, as 
PDGFs have been implicated in the formation of the extracellular matrix 
(Owen, Geyer and Antoniades, 1982; Majack, Cook and Bornstein, 1985). 
5.4.3 No PDGFR compensation occurs due to the reduction 
of PDGF-B/PDGFRβ signalling between PCs and ECs 
Although no differences in the distribution of perivascular cells was detected 
in PDGF-Bret mutant aortas, we looked at whether the percentages of different 
populations of endothelial, haematopoietic and perivascular cells were altered 
in these mutants by flow cytometry. We found no differences in the populations 
of cells analysed, including PDGFRβ+ perivascular cells, suggesting that 
PDGF-Bret mutation does not affect the cell composition of the AGM nor 
induces a compensation by increasing PDGFRβ expression. As PDGF-B is 
also a ligand for PDGFRα [143], we also analysed PDGFRα expression in 
mutant embryos to determine whether there was a compensation for the 
reduced PDGF-B/PDGFRβ signalling. PDGFRα expression was not altered in 
any of the populations analysed. These data indicate that PDGF-B retention 
motif deletion and consequent reduction in PDGF-B/PDGFRβ signalling is not 
compensated by an increase in PDGF-B receptors. PDGF-B binding to 
PDGFRα was shown to activate similar downstream signalling transduction 
pathways as its binding to PDGFRβ in vitro, this might not be the case during 
embryonic development in vivo [143]. Indeed, a study showed that when the 
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intracellular domain of PDGFRβ is interchanged with the one of PDGFRα, the 
vascular defects and retinopathy occurring in PDGFRβ and PDGF-B KO 
embryos as well as PDGF-Bret KO embryos persist, suggesting that PDGFRα 
signalling has different biological functions to PDGFRβ and cannot 
compensate for the lack of PDGF-B/PDGFRβ signalling in vivo [214].  
We also sought to determine whether the haemogenic endothelium was 
affected by PDGF-Bret mutation by crossing mutant mice with Runx1-IRES-
GFP mice. However, these data could not be used, as Runx1-GFP mice were 
heterozygous for GFP and differences in Runx1-GFP expression were later 
found between Runx1GFP/GFP compared to Runx1GFP/+ AGMs analysed by flow 
cytometry. Unfortunately PDGF-Bret;Runx1-GFP mice were not genotyped for 
Runx1-GFP, and therefore we could not determine whether embryos were 
GFP/+ or GFP/GFP (data not shown). It would be interesting to repeat these 
experiments using Runx1GFP/GFP mice to determine whether HECs are affected 
in PDGF-Bret mutants.  
5.4.4 Adult haematopoiesis is not affected by PDGF-B 
retention motif deletion 
As PDGF-Bret KO mice survive into adulthood and E11 AGMs seem to be 
unable to produce LTR-HSCs, we looked at adult haematopoiesis in these 
mutants. No differences in BM HSPC numbers were detected in PDGF-Bret 
KO mice, suggesting that the deletion of PDGF-B retention motif does not 
affect adult haematopoiesis. Furthermore, LSK-SLAM analysis showed no 
significant differences in the percentages of LSK, HPC1, HPC2, HSCs and 
MPPs (Figure 72), which is not surprising, since no defects were detected in 
the number and types of HSPC colonies obtained in PDGF-Bret mutants 
(Figure 71). A slight, albeit not significant decrease in the number of HSCs and 
MPPs could be detected. There was however a high variation between 
biological replicates, and the number of samples was low (4 WT, 5 HET and 3 
KO BMs). Therefore, no conclusions can be drawn on whether this is a real 
trend. In addition, BM from both PDGF-Bret HET and KO mice could 
reconstitute both primary and secondary irradiated recipients (Figure 73), 
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suggesting that HSCs are not affected by this mutation. Nonetheless, it would 
be important to add a few additional samples to confirm the LSK-SLAM data.  
5.4.5 Conclusions and future work 
In this Chapter, PDGF-B retention motif KO was shown to have no 
consequences for adult haematopoiesis, as mutant BMs were able to 
reconstitute irradiated recipients in both primary and secondary 
transplantations. However, PDGF-Bret KO AGMs failed to reconstitute 
secondary recipients, suggesting that these AGMs are unable to produce self-
renewing HSCs. These data need to be confirmed with further secondary 
transplantation analysis, as the number of animals transplanted was low (n=2 
into 4 irradiated recipients), and reconstitution levels of primary recipients were 
also generally low.  
Overall, the effects of PDGF-Bret mutation appear to be milder than in PDGFRβ 
KO AGMs, with a lower increase in αSMA expression in mutant aortas, as well 
as no changes in AGM HSPCs. This is in line with previous reports that the 
retention deletion has less severe effects in mice compared to a full KO of 
PDGF-B or PDGFRβ [157,158,210]. As expected, following the results 
obtained in Chapter 4, pericyte/vSMC recruitment to the DA is not affected in 
the absence/reduction of PDGF-B/PDGFRβ signalling.  
To conclude, it remains unclear how defective retention of PDGF-B affects the 
dorsal aorta, and whether and how PDGF-B/PDGFRβ signalling is affected. 
As PDGF-B is still produced and functional, at least a certain level of PDGF-
B/PDGFRβ signalling is bound to occur between aortic pericytes and 
endothelial cells. A better characterisation of this mouse model needs to be 
conducted in order to make any conclusions of the effects of a possible defect 




Chapter 6 Conclusions and future 
considerations 
Haematopoietic stem cells have been widely used to treat haematological 
malignancies and other blood/immune diseases, and have the potential to treat 
a broader range of genetic disorders, such as metabolic disorders, where 
patients lack the production of certain enzymes. Unfortunately, such therapies 
still rely on the availability of compatible donors, as it has yet not been possible 
to generate and expand these cells in vitro. Understanding how HSC 
generation, maintenance and expansion occurs in vivo could provide the cues 
necessary for their culture in vitro.  
In the last decades, much has been discovered regarding HSC generation 
during embryonic development. HSCs have been shown to arise from 
haemogenic endothelial cells and require signals from the microenvironment 
for this process to occur. However, the signals and cells involved in HSC 
generation are still poorly understood. This thesis has shed a new light on the 
cells composing the HSC-generating microenvironment and the signals they 
produce, and uncovered possible multiple origins for embryonic HSCs.  
6.1 Perivascular cells surrounding the midgestation 
dorsal aorta might act as a niche for HSC 
generation and/or maintenance 
In Chapter 1, three perivascular cell populations were defined and separated 
based on the expression of the perivascular cell surface markers NG2 and 
PDGFRβ. Pericytes/vSMCs, in closer contact with the aortic endothelium 
express both markers, while a few layers of cells surrounding them only 
express PDGFRβ. The remaining mesenchyme, further from the DA does not 
express any of these markers. Using bulk RNA sequencing analysis of these 
three populations we found that the PC/vSMC population is enriched in HSC 
niche related transcripts that were previously described in perivascular cells of 
the adult BM. In the next several months, the ability for each of these stromal 




As a subset of PCs was shown to express CD146, it would also be interesting 
to further separate them into CD146+ and CD146- PCs, perform RNA 
sequencing and test their ability to support haematopoiesis and determine 
whether they differ in their niche potential. Recent data in our lab found that 
the deletion of Runx1 from PC/vSMCs impairs aortic haematopoiesis, with the 
failure to generate HSCs. Interestingly, recent single cell RNA sequencing in 
our lab showed that most Runx1+ PC/vSMCs also express CD146. One study 
showed that CD146+ but not CD146- human perivascular cells support cord 
blood CD34+ HPSCs [117].  It would be interesting to test whether CD146+ 
PCs/vSMCs in the AGM support HSCs better than their CD146- counterpart.  
6.2 PDGFRβ signalling is required for AGM 
haematopoiesis 
As the two closest populations of perivascular cells to the aortic endothelium 
express PDGFRβ, and since PDGFRβ was shown to be required for HSC 
specification [148], Chapters 4 and 5 looked at the role of PDGF-B/PDGFRβ 
signalling in midgestation haematopoiesis. We found that the germline KO of 
PDGFRβ leads to the complete absence of HSCs in the AGM and reduced 
HSPC numbers. HSPCs in other haematopoietic organs at midgestation were 
not affected. As injections of PDGFRβ KO E14 FL were shown to reconstitute 
irradiated recipients [201], our data suggest that not all HSCs are generated in 
the AGM region, or that they do not become fully functional before migrating 
to the FL. We also found that PDGF-Bret KO AGM transplantations fail to 
reconstitute secondary recipients, suggesting that a defective PDGF-
B/PDGFRβ signalling affects HSCs self-renewal capacity. However, it remains 
unclear how PDGF-Bret mutation affects PDGF-B/PDGFRβ signalling in these 
mice.  
We are currently performing single cell RNA sequencing in E11 WT and KO 
AGMs to investigate how gene expression and signalling pathways are altered 




6.3 Pericytes/vSMC recruitment to the DA is not 
affected by defects in PDGF-B/PDGFRβ signalling 
As PDGF-B/PDGFRβ signalling was shown to be required for the recruitment 
of pericytes/vSMCs to the endothelial wall of small blood vessels, we 
investigated whether aortic perivascular cells were also absent or their 
numbers reduced in the DA of PDGFRβ KO and PDGF-Bret KO embryos. We 
found that PDGF-B/PDGFRβ signalling is not responsible for the proper 
investment of the aortic endothelium by PCs/vSMCs, as these populations 
were still present and with a similar distribution in both mutant lines (in 
PDGFRβ KO embryos, NG2+ αSMA+ were present in the same location as 
PC/vSMCs but did not express PDGFRβ). Interestingly, the phenotype of this 
population was altered in PDGFRβ KO embryos, with a significant decrease in 
NG2 expression and an increase in αSMA expression. Expression levels of 
NG2 and αSMA need to be further tested on PDGF-Bret KO embryos, as it 
remains unclear if this mutation affects PC/vSMC phenotype.  
To test whether these phenotypic changes alter the niche for HSC 
generation/maintenance, co-culture experiments will be performed to compare 
the HSC supportive capacity of stromal cells from PDGFRβ WT and KO 
embryos.  
6.4 Possible multiple origins for developing HSCs 
Since PDGFRβ KO affects AGM HSPCs and we found that midgestation 
HSPCs do not express PDGFRβ, we hypothesised that PDGFRβ could mark 
haematopoietic cell precursors, and its disruption could affect HSC generation. 
Using PDGFRβ-Cre;TdTomato or PDGFRβ-Cre;mTmG mice, we found that a 
subset of embryonic HSPCs derive from PDGFRβ precursors. This subset 
contained bona fide HSCs that were able to reconstitute irradiated recipients, 
and were still present in the adult BM. As HSCs are absent in PDGFRβ KO 
AGM, it is likely that PDGFRβ-derived HSCs come from the AGM region. To 
test this, immunohistochemistry was performed on PDGFRβ-Cre;mTmG 
cryosections, and we found that endothelial cells and some hematopoietic 




PDGFRβ and haematopoiesis. To further understand at which stage these 
precursors appear and validate the findings obtained with the PDGFRβ-Cre 
mouse line, we established a collaboration with H. Grajal Cuervo at the 
University of Illinois, Chicago, whose lab works with PDGFRβ-P2A-
CreERT2;mTmG mice. Pregnant dams were injected with tamoxifen at E7, E8 
and E9, and embryos were harvested at E11. Analysis of these embryos is 
currently underway, but we have been able to confirm that GFP expression is 
found in E11 ECs from all the three different tamoxifen injection timepoints (not 
shown). 
In addition, we are currently performing haematopoietic progenitor assays in 
other haematopoietic organs at stages that precede AGM haematopoiesis (E8-
E9) up to E11 to test whether PDGFRβ+ precursors only give rise to definitive 
haematopoiesis. If this is the case, HP colonies will be only found in tissues 
after E10.5. 
6.5 Conclusions 
Overall, this study has found that there are at least two origins of HSCs in the 
embryo, one of which, derives from PDGFRβ+ precursor cells, that give rise to 
fully functional HSCs in the AGM. Defects in PDGFRβ signalling appear to 
either impair the maturation or the maintenance of PDGFRβ-derived HSCs, as 
haematological defects can only be detected at E11.5, but not before. 
Importantly, PDGFRβ-derived HSCs are still present in the adult. Finally, 
Whether PDGFRβ signalling plays a role in the niche for HSC generation 
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